POS AM 1 mainbody.htm MAINBODY mainbody.htm
 
As filed with the Securities and Exchange Commission on  June ___, 2013
 
Registration No.  333-181361
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
_____________________
 
Post-Effective Amendment No. 1
to
FORM S-1
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
 
_________________
 
Assured Pharmacy, Inc.
(Exact name of registrant as specified in its charter)
___________________
 
Nevada
5912
98-0233878
(State or other jurisdiction of
incorporation or organization)
(Primary Standard Industrial
Classification Code Number)
(I.R.S. Employer
Identification Number)
___________________

5600 Tennyson Parkway, Suite 390
Plano, Texas 75024
(972) 473-4033
(Address, including zip code, and telephone number, including area code, of principal executive offices)
___________________
 
Robert DelVecchio
Chief Executive Officer
5600 Tennyson Parkway, Suite 390
Plano, Texas 75024
(972) 473-4033
(Name, address, including zip code, and telephone number, including area code, of agent for service)
___________________
 
With copies to:
 
Jennifer Eichholz, Esq.
Quarles & Brady LLP
411 East Wisconsin Avenue, Suite 2040
Milwaukee, Wisconsin 53202
Phone: (414) 277-5409
Fax: (414) 978-8918
___________________
 
Approximate date of commencement of proposed sale to the public:
As soon as practicable after this registration statement becomes effective.
 
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.   x
 
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  o
 
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  o
 
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  o
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer  o
 
Accelerated filer                    o
Non-accelerated filer    o   
(Do not check if a smaller reporting company)
Smaller reporting company  x
 
Calculation of Registration Fee
 
Title of Each Class of Securities to be Registered
Amount to be
Registered
Proposed Maximum
Offering Price
Per Share (1)
Proposed Maximum
Aggregate Price(1)
Amount of
Registration
Fee (1)(2)(3)
Common stock, par value $0.001 per share, issuable upon exercise of Warrants
2,292,067
$0.675
$1,547,145
$177.30
 
(1)
Estimated pursuant to Rule 457(c) under the Securities Act of 1933 (based on the average of the bid and asked prices of the registrant’s common stock May 8, 2012) for purposes of calculating the registration fee in accordance with Rule 457(c) and (f) under the Securities Act of 1933.
(2)
(3)
Calculated under Section 6(b) of the Securities Act of 1933 as .00011460 of the aggregate offering price.
Previously paid.
 
The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine. 


 
 
 
 
 
 
The information in this prospectus is not complete and may be changed. We have filed a registration statement with the Securities and Exchange Commission relating to this prospectus. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is declared effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.
 
SUBJECT TO COMPLETION, DATED  JUNE ____, 2013

 
 
2,292,067 Shares
 
logo
 
Assured Pharmacy, Inc.
 
Common Stock
 
This prospectus relates to the offer and sale or other disposition of  2,292,067, shares of our common stock issuable on exercise of warrants (at exercise prices ranging from $0.90 to $1.52 per share) by the selling stockholders named in this prospectus.   This prospectus may be used by the selling stockholders named herein to resell, from time to time, those shares of our common stock included herein which are issuable upon the exercise of warrants.  The issuance of the shares upon exercise of warrants is not covered by this prospectus; only the resale of the shares underlying the warrants is covered. For information about the selling stockholders see “Selling Stockholders” on page 52.
 
Our common stock is presently quoted on the OTC Markets under the trading symbol “APHY”. On  June 4, 2013, the last sale price of our common stock as reported by the OTC Markets was $0.89 per share.
 
The selling stockholders may offer to sell their shares of common stock from time to time through public or private transactions, on or off of the OTC Markets at prevailing market prices, at prices related to the prevailing market prices, at fixed prices that may be changed, or at privately negotiated prices. We will not receive any of the proceeds from the sale of the shares of common stock by the selling stockholders, but will receive proceeds related to the exercise for cash of warrants held by the selling stockholders.

 
The selling stockholders, and any participating broker-dealers, may be deemed to be “underwriters” within the meaning of the Securities Act of 1933, and any commissions or discounts given to any such broker-dealer may be regarded as underwriting commissions or discounts under the Securities Act.  The selling stockholders have informed us that they do not have any agreement or understanding, directly or indirectly, with any person to distribute their common stock.

 
Persons effecting transactions in the shares should confirm the registration of these securities under the securities laws of the states in which transactions occur or the existence of applicable exemptions from such registration.
 
The shares being offered are highly speculative and involve a high degree of risk.  They should be considered only by persons who can afford the loss of their entire investment. See “Risk Factors” beginning on page 5.
 
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.
 
The date of this prospectus is ______________, 2013.
 
_____________________________
 
 
 
 

 
 
- ii -

 

 
logo
 

 
   
 
Page No.
   
1
   
1
   
2
   
5
   
16
   
16
   
16
   
17
   
27
   
28
   
41
   
42
   
44
   
47
   
51
   
54
   
56
   
58
   
59
   
66
   
66
   
67
   
II - 1
 
You should rely only on the information contained in this prospectus or in any free-writing prospectus we may authorize. We have not and the selling stockholders have not authorized anyone to provide you with additional or different information. The information in this prospectus or any free-writing prospectus may only be accurate as of its date, regardless of its time of delivery or of any sale of shares of common stock. This prospectus does not constitute an offer to sell, or a solicitation of an offer to buy, any securities offered hereby in any jurisdiction where, or to any person to whom, it is unlawful to make such offer or solicitation.
 
 
 
 
 
 
 
- iii -

 
 
 
 
 

 This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, or SEC, utilizing a “shelf” registration process or continuous offering process. Under this shelf registration process, the selling stockholders may, from time to time, sell the securities described in this prospectus in one or more offerings. This prospectus provides you with a description of the securities that may be offered by the selling stockholders. Each time a selling stockholder sells securities, the selling stockholder is required to provide you with this prospectus and, in certain cases, a prospectus supplement containing specific information about the selling stockholder and the terms of the offering. Any prospectus supplement may add, update, or change information in this prospectus. If there is any inconsistency between the information in this prospectus and any prospectus supplement, you should rely on the information in that prospectus supplement.

 Please read “Where You Can Find More Information.” You are urged to read this prospectus carefully, including the “Risk Factors” in their entirety before investing in our securities.
 

 This prospectus includes “forward-looking statements” within the meaning of the federal securities laws that involve risks and uncertainties. Forward-looking statements include statements we make concerning our plans, objectives, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs and other information that is not historical information.  Some forward-looking statements appear under the headings “Prospectus Summary,” “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Business.” When used in this prospectus, the words “estimates,” “expects,” “anticipates,” “projects,” “forecasts,” “plans,” “intends,” “believes,” “foresees,” “seeks,” “likely,” “may,” “might,” “will,” “should,” “goal,” “target” or “intends” and variations of these words or similar expressions (or the negative versions of any such words) are intended to identify forward-looking statements. All forward-looking statements are based upon information available to us on the date of this prospectus.
 
These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including, among other things, the matters discussed in this prospectus in the sections captioned “Prospectus Summary,” “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Business.” Some of the factors that we believe could affect our results include:
 
   
limitations on our ability to continue operations and implement our business plan;
   
our history of operating losses;
   
the timing of and our ability to obtain financing on acceptable terms;
   
dependence on key supplier;
   
dependence on third-party payors;
   
the effects of changing economic conditions;
   
the loss of members of the management team or other key personnel;
●   
changes in governmental laws and regulations, or the interpretation or enforcement thereof and related compliance costs;
●   
competition from larger, more established companies with greater economic resources than we have;
 ●   
costs and other effects of legal and administrative proceedings, settlements, investigations and claims, which may not be covered by insurance;
●   
costs and damages relating to pending and future litigation;
●   
control by our principal equity holders; and
●   
the other factors set forth herein, including those set forth under “Risk Factors.”
 
There are likely other factors that could cause our actual results to differ materially from the results referred to in the forward-looking statements. All forward-looking statements attributable to us in this prospectus apply only as of the date of this prospectus and are expressly qualified in their entirety by the cautionary statements included in this prospectus. We undertake no obligation to publicly update or revise forward-looking statements to reflect events or circumstances after the date made or to reflect the occurrence of unanticipated events, except as required by law.
 
 
 

 
 

 
 
 
This summary highlights certain significant aspects of our business and this offering, but it is not complete and does not contain all of the information that you should consider before making your investment decision. You should carefully read the entire prospectus and the information incorporated by reference into this prospectus, including the information presented under the section entitled “Risk Factors” and the financial data and related notes, before making an investment decision. This summary contains forward-looking statements that involve risks and uncertainties. Our actual results may differ significantly from future results contemplated in the forward-looking statements as a result of factors such as those set forth in “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements.” Certain historical information in this prospectus has been adjusted to reflect the 1-for-180 reverse stock split of our common stock that was effective April 15, 2011.
 
In this prospectus, unless the context indicates otherwise: “Assured Pharmacy,” the “Company,” “we,” “our,” “ours” or “us” refer to Assured Pharmacy, Inc., a Nevada corporation, and its subsidiaries.
 
Our Company
 
We were organized as a Nevada corporation on October 22, 1999, under the name Surforama.com, Inc. and previously operated under the name eRXSYS, Inc.  We changed our name to Assured Pharmacy, Inc. in October 2005.  Since May 2003, we have been engaged in the business of establishing and operating pharmacies that specialize in dispensing highly regulated pain medication for chronic pain management.  Because our focus is on dispensing medication, we typically will not keep in inventory non-prescription drugs, or health and beauty related products, such as walking canes, bandages and shampoo. We primarily derive our revenue from the sale of prescription medications.   The majority of our business is derived from repeat business from our customers.
 
We currently have four operating pharmacies, each of which is wholly owned through a subsidiary. The opening date and locations of our pharmacies are as follows:
 
Location
 
Opening Date
 
Riverside, California
 
June 10, 2004
Kirkland, Washington
 
August 11, 2004
Gresham, Oregon
 
January 26, 2007
Kansas City, Kansas
 
November 28, 2011

 
In February 2004, we entered into an agreement with TAPG, L.L.C., a Louisiana limited liability company (“TAPG”), for the purpose of operating up to five pharmacies and incorporated Assured Pharmacies Northwest, Inc. (“APN”), formerly known as Safescript Northwest, Inc., to operate these pharmacies.  Under this agreement, TAPG was required to contribute financing in the amount of $335,000 for each pharmacy and we contributed certain intellectual property rights and sales and marketing services.  APN operates the pharmacy in Kirkland, Washington and previously operated another pharmacy in Portland, Oregon which was closed in December 2008 and consolidated with the operations of our Gresham, Oregon pharmacy.  We initially owned 75% of APN’s outstanding capital stock and TAPG owned the remaining 25%. From time to time, we advanced interest-free loans to sustain operations at the pharmacies operated by APN.  In March 2006, the outstanding principal balance on these loans was converted into APN capital stock resulting in us increasing our ownership interest in APN from 75% to 94.8%, which resulted in TAPG’s ownership in APN being diluted to own the remaining 5.2% of APN’s outstanding capital stock.  In June 2011, we acquired all of the outstanding capital stock of APN held by TAPG pursuant to the terms of a Stock Purchase Agreement dated as June 30, 2011.  Pursuant to this agreement, we issued TAPG 300,000 restricted shares of our common stock and TAPG agreed to cancel $17,758 in principal and interest we owed to TAPG.  As a result of this transaction, APN became our wholly owned subsidiary.
 
 
 
 
 
 
 
 

 
In April 2003, we entered into an agreement with TPG, L.L.C., a Louisiana limited liability company (“TPG”), for the purpose of funding the establishment of and operating up to fifty pharmacies and incorporated Assured Pharmacies, Inc. (“API”) to operate these pharmacies.  Under this agreement, TPG was required to contribute financing in the amount of $230,000 for each pharmacy and we contributed certain intellectual property rights and sales and marketing services.  In exchange for the foregoing contributions, we owned 51% of API’s outstanding capital stock and TPG owned the remaining 49%.  API operates the pharmacies in Santa Ana and Riverside, California.  In December 2012, we consolidated the operations of the Santa Ana pharmacy into our Riverside pharmacy.  We entered into a Purchase Agreement with TPG and acquired all of the outstanding capital stock of API held by TPG for the purchase price of $460,000 in cash and the issuance of 278 restricted shares of our common stock.  As a result of this transaction, API also became our wholly owned subsidiary.  The cash component of the purchase price is payable in monthly installments over time.  As of May 31, 2013 , we had paid TPG an aggregate of $332,500 including principal and interest and certain other obligations to TPG under the Purchase Agreement.  Due to our current financial condition, we did not make required monthly installment payments of $10,000 starting in September 15, 2012 through May 15, 2013 and may be unable to make the delinquent payments or the final payment due to TPG which includes principal and interest on or before July 15, 2013.  As of May 31, 2013 , we owe TPG $242,873 plus all accumulated accrued interest.  If we remain unable to fulfill our obligations to TPG under the Purchase Agreement, we will attempt to restructure and extend the terms of payments due to TPG, but can provide no assurance we will be able to do so on acceptable terms or even at all.  In order to secure our obligations under the Purchase Agreement, TPG holds a security interest in the shares of API capital stock acquired by us under the Purchase Agreement.  If TPG should demand payment and we are unable to renegotiate the terms for our outstanding obligations to TPG under the Purchase Agreement, TPG could declare us in default and may seize the shares of API capital stock acquired by us under the Purchase Agreement, which would result in API no longer being a wholly owned subsidiary and have a material adverse effect on our business, operating results and financial condition.  TPG has not issued a notice of default relating to our failure to make the monthly installment payments required under the Purchase Agreement.
 
Our pharmacy in Gresham, Oregon is operated by Assured Pharmacy Gresham, Inc, and our pharmacy in Leawood, Kansas is operated by Assured Pharmacy Kansas, Inc.
 
Company Information
 
Our principal office is located at 5600 Tennyson Parkway, Suite 390, Plano, TX 75024 and our phone number is 972-473-4033.  We maintain a website at www.assuredrxservices.com. Information contained on our website is not a part of, and is not incorporated by reference into, this prospectus.
The Offering
 
Issuer
Assured Pharmacy, Inc.
   
Common stock offered
by the selling stockholders
 
Up to 2,292,067 shares, of which:
 
     ●  2,192,067 shares are issuable upon the exercise of warrants at an exercise price of $0.90 per share;
     ●  100,000 shares are issuable upon the exercise of warrants at an exercise price of $1.52 per share; and
   
Offering Price and Alternative Plan
of Distribution
All shares being offered are being sold by existing stockholders without our involvement. The offering price will thus be determined by market factors and the independent decisions of the selling stockholders.
   
Common stock outstanding
after this offering
8,604,895 shares
   
Use of proceeds
 
The selling stockholders will receive all of the proceeds from this offering and we will not receive any proceeds from the sale of shares in this offering. Any proceeds received by us in connection with the exercise of warrants to purchase shares of our common stock by the selling stockholders in connection with this offering will be used for general corporate purposes. See “Use of Proceeds.”
   
Risk factors
See “Risk Factors” beginning on page 5 of this prospectus for a discussion of some of the factors you should carefully consider before deciding to invest in our common stock.
   
OTC trading symbol
 
APHY
 
 
 
 
 
 

 
 
 
The number of shares of our common stock outstanding after this offering is based on 6,312,828 shares outstanding as of May 31, 2013, plus an aggregate of 2,292,067 shares of common stock subject to outstanding warrants assured to be exercised by certain selling stockholders for the purpose of selling shares in this offering.
 
SELECTED HISTORICAL FINANCIAL DATA
 
The following condensed statement of operations data for the years ended December 31, 2012 and 2011, and the selected balance sheet data at December 31, 2012 and 2011, are derived from our audited financial statements and the related notes.  Our financial statements and the related notes as of December 31, 2012 and 2011 and for the two years then ended are included elsewhere herein.  The unaudited selected statement of operations data for the three months ended March 31, 2013 and 2012, and the unaudited consolidated selected balance sheet data at March 31, 2013, are derived from unaudited financial statements, which have been prepared on a basis consistent with our audited financial statements and, in the opinion of management, include all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of our financial position and results of operations.  The results of operations for any interim period are not necessarily indicative of results to be expected for the entire year,   The following data should be read in conjunction with "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS" and our financial statements and the related notes included elsewhere in this prospectus.
 
Consolidated Statement of Operations Data:
 
   
For the year ended
December 31,
   
For the three months ended
March 31,
(Unaudited)
 
   
2012
   
2011
   
2013
   
2012
 
                         
Sales
  $ 14,145,533     $ 16,444,573     $ 2,893,295     $ 3,647,410  
Costs of sales
    11,078,407       13,220,684       2,221,035       2,908,421  
Gross profit
    3,067,126       3,223,889       672,260       738,989  
Total operating expenses
    5,864,263       5,990,868       1,346,049       1,301,099  
Loss from continuing operations before non-controlling interest
    (2,797,137 )     (2,766,979 )     (673,789 )     (562,110 )
Total other expenses (net)
    1,208369       491,982       459,224       334,917  
Net loss from operations before non-controlling interest
    (4,005,506 )     (3,258,961 )     (1,133,013 )     (897,027 )
Net loss attributable to non-controlling interest
    -       (12,051 )     -       -  
Net loss
  $ (4,005,506 )   $ (3,271,012 )   $ (1,133,013 )   $ (897,027 )

Balance Sheet Data:
 
   
As of December 31,
    As of March 31, 2013  
   
2012
   
2011
   
(Unaudited)
 
                   
Cash and cash equivalents
  $ 21,298     $ 23,316     $ 11,785  
Working capital (1)
    (6,312,121 )     (3,672,556 )     (6,892,280 )
Total assets
    2,221,498       2,966,059       2,330,117  
Total liabilities
    8,708,571       6,295,187       9,562,590  
Stockholders’ deficit
    (6,487,073 )     (3,329,128 )     (7,232,473 )

(1)   Working capital represents total current assets less total current liabilities.
 
 
 
 

 
 
 
 
 
 
Investment in our common stock involves a number of substantial risks.  You should not invest in our stock unless you are able to bear the complete loss of your investment. In addition to the risks and investment considerations discussed elsewhere in this prospectus, the following factors should be carefully considered by anyone purchasing the securities offered through this prospectus. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. If any of the following risks actually occur, our business could be harmed. In such case, the trading price of our common stock could decline and investors could lose all or a part of the money paid to buy our common stock.
 
Risks Related to Our Business and Industry
 
If we do not obtain additional financing, we could be required to discontinue operations.
 
As of March 31, 2013, we had cash in the amount of $11,785 and total liabilities in the amount of $9,562,590.  During fiscal 2012, we received $350,400 in financing in debt offerings exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). From January 1, 2013 through May 30, 2013 we received $860,000 in financing in equity offerings exempt from the registration requirements of the Securities Act.  However, we still require additional financing to implement our business plan for the next twelve months and open any additional pharmacies.  We also had a working capital deficit of $6,892,280 as of March 31, 2013.  Our current cash on hand is insufficient for us to operate our four existing pharmacies at the current level for the next twelve months.  Our business plan calls for ongoing expenses in connection with salary expense and establishing additional pharmacies. These expenditures are anticipated to be approximately $4,600,000 for the next twelve months.  In order to continue to pursue our business plan to establish and operate additional pharmacies, we will require additional funding.  However, if we are not able to secure additional funding, the implementation of our business plan will be delayed and our ability to expand and develop additional pharmacies will be impaired and we could be forced to cease operations. We intend to secure additional funding through additional debt or equity financing arrangements, increased sales generated by our operations and reduced expenses. There can be no assurance that we will be successful in raising all of the additional funding that we are seeking. 

If we are unable to support our current debt service and liabilities as they come due, we will probably be required to discontinue operations.
 
Our business is highly leveraged, and had total debt and other liabilities in the amount of $9,562,590 net of unamortized discounts of $288,616 at March 31, 2013. This debt includes the $2,677,168 of unsecured convertible notes described herein. In February 2013, we converted $3,534,793 in trade payables and the remaining balance of $293,734 in a secured note into a one year note payable with an interest rate of 6.25 percent with our primary wholesaler.  If we are unable to meet our debt service obligations or default on our obligations in any other way, even if we are otherwise generating earnings and positive cash flow, we could lose substantially all of our business assets as well as being held liable for any deficiency in payment. The net result of such a failure would likely be the end of our business operations and a complete loss of your investment.
 
Approximately $2,435,195  in principal amount of unsecured convertible debentures is  or will become due in 2013, of which $500,000 is past due.
 
As of March 31, 2013 we had a cash balance of $11,785. Over the last several years, we have been substantially dependent on funding our operations through the private sale of both equity and debt securities.  Of the $2,435,195 in principal amount of our outstanding convertible debentures coming due in 2013 or already due, $750,000 is currently past due. We are attempting to restructure the terms of the $500,000 in principal amount of our outstanding unsecured convertible debentures which had a maturity date in 2012, but can provide no assurance that the holders of such securities will agree to extend the maturity date on these securities on acceptable terms.  On May 3, 2013, Hillair Capital issued a notice of default on the 16% Senior Convertible Debentures issued on May 16, 2011, August 22, 2011, November 24, 2011 and July 19, 2012 with an aggregate principal amount of $1,000,000.  We are also discussing the possibility of these debt holders converting such securities into equity.  If these debenture holders choose not to convert these securities which have a maturity date in 2012 into equity, we will need to repay such debt, or reach an agreement with the debt holders to modify the terms thereof.  If we are forced to repay such debt and are unable to meet these obligations or default on our obligations in any other way, even if we are otherwise generating positive earnings, we could lose substantially all of our business assets as well as being held liable for any deficiency in payment. The net result of such a failure would likely be the end of our business operations and a complete loss of your investment.
 
We may default on our outstanding obligations under a Purchase Agreement with TPG.
 
We entered into a Purchase Agreement with TPG and acquired all of the outstanding capital stock of API held by TPG for the purchase price of $460,000 in cash and the issuance of 278 restricted shares of our common stock.  As a result of this transaction, API also became our wholly owned subsidiary.  The cash component of the purchase price is payable in monthly installments over time.  As of May 31, 2013, we had paid TPG an aggregate of $332,500 including principal and interest and certain other obligations to TPG under the Purchase Agreement.  Due to our current financial condition, we did not make the required monthly installment payment of $10,000 starting in September 15, 2012 through May  15, 2013 and may be unable to make the delinquent payments or the final payment due to TPG which includes principal and interest on or before July 15, 2013.  As of May 31, 2013, we owe TPG $242,873 plus all accumulated accrued interest.  If we remain unable to fulfill our obligations to TPG under the Purchase Agreement, we will attempt to restructure and extend the terms of payments due to TPG, but can provide no assurance we will be able to do so on acceptable terms or even at all.  In order to secure our obligations under the Purchase Agreement, TPG holds a security interest in the shares of API capital stock acquired by us under the Purchase Agreement.  If TPG should demand payment and we are unable to renegotiate the terms for our outstanding obligations to TPG under the Purchase Agreement, TPG could declare us in default and may seize the shares of API capital stock acquired by us under the Purchase Agreement, which would result in API no longer being a wholly owned subsidiary and have a material adverse effect on our business, operating results and financial condition.  TPG has not issued a notice of default relating to our failure to make the monthly installment payments required under the Purchase Agreement.
 
 
 
 
 
 
 
 
 
 
There is substantial doubt regarding our ability to continue as a going concern.
 
As noted in our consolidated financial statements, we had an accumulated stockholders’ deficit of approximately $44.1 million and recurring losses from operations as of March 31, 2013.  We also had a working capital deficit of approximately $6.9 million as of March 31, 2013 and debt with maturities in the year ended December 31, 2013 in the amount of approximately  $2.8 million as of March 31, 2013.  From January 1, 2013 through May 31, 2013, the Company has completed equity offerings of $860,000 and restructured the credit facility with its primary wholesaler.  We intend to fund operations through raising additional capital through debt financing and equity issuances, increased sales, and reduced expenses, which may be insufficient to fund our capital expenditures, working capital or other cash requirements for the year ending December 31, 2013. We are continuing to seek additional funds to finance our immediate and long term operations. The successful outcome of future financing activities cannot be determined at this time and there is no assurance that if achieved, we will have sufficient funds to execute our intended business plan or generate positive operating results. These factors, among others, raise substantial doubt about our ability to continue as a going concern.  The audit reports of BDO USA, LLP and UHY, LLP for the fiscal year ended December 31, 2012 and 2011, respectively contain a paragraph that emphasizes the substantial doubt as to our continuance as a going concern.  This is a significant risk that we may not be able to remain operational for an indefinite period of time.
 
If we are unable to generate significant net revenues from our operations, our business will fail.
 
As we pursue our business plan, we are incurring significant expenses. We incurred operating expenses for the year ended December 31, 2012 in the amount of $5,091,210 (excluding non-cash operating expenses of $773,053) and had gross profit of $3,067,126 on sales of $14,145,533 for the same period. We incurred operating expenses for the year ended December 31, 2011 in the amount of $4,455,678 (excluding non-cash operating expenses of $1,535,190) and had gross profit of $3,223,889 on sales of $16,444,573 for the same period.  We have a history of operating losses and cannot guarantee profitable operations in the future.  The success and viability of our business is contingent upon generating significant net revenues from the operations of our pharmacies such that we are able to pay our operating expenses and operate our business at a profit. Currently, we are unable to generate sufficient revenues from our existing business to pay our operating expenses and operate at a profit. In the event that we remain unable to generate sufficient revenues from our pharmacies to pay our operating expenses, we will not be able to achieve profitability or continue operations. In such circumstance, you may lose all of your investment.

Failure to maintain optimal inventory levels could increase our inventory holding costs or cause us to lose sales, either of which could have a material adverse effect on our business, financial condition and results of operations.
 
We need to maintain sufficient inventory levels to operate our business successfully as well as meet our customers’ expectations. However, we must also guard against the risk of accumulating excess inventory. We are exposed to inventory risks as a result of our growth, changes in physician prescription writing practices, manufacturer backorders and other vendor-related problems.  An additional risk to our ability to maintain optimal inventory levels is that our financial condition may inhibit us from securing vendor financing which is a necessity in maintaining proper inventory levels. Carrying too much inventory would increase our inventory holding costs, and failure to have inventory in stock when a prescription is presented for fulfillment could cause us to lose that prescription, lose that customer, or lose the referring physician, any of which could have a material adverse effect on our business, financial condition and results of operations.
 
If we are unable to hire, retain and motivate qualified personnel, we may not be able to grow effectively and execute our business plan.
 
We depend on the services of our senior management. We have retained the services of Robert DelVecchio to serve as our Chief Executive Officer, Mike Schneidereit to serve as our Chief Operating Officer and Brett Cormier to serve as our Chief Financial Officer. Our success depends on the continued efforts of Messrs. DelVecchio, Schneidereit and Cormier. The loss of the services of any of these individuals could have an adverse effect on our business, prospects, financial condition, and results of operations.
 
As our business develops, our success is largely dependent on our ability to hire and retain additional highly qualified managerial, sales and technical personnel. These managerial, technical and sales personnel are generally in high demand and we may not be able to attract the staff we need at a cost that is within our operating budget. In addition, we may lose employees or consultants that we hire due to higher salaries and fees being offered by other businesses. If we do not succeed in attracting excellent personnel or retaining or motivating existing personnel, we may be unable to grow effectively and implement our business plan.
 
 

 
 
 
 
 
 
Pending and future litigation could subject us to significant monetary damages and/or require us to change our business practices.
 
We are subject to risks relating to litigation and other proceedings in connection with the dispensing of pharmaceutical products by our pharmacies. See the subsection entitled “Legal Proceedings” for a description of legal proceedings pending against us. While we believe that the disclosed suit is without merit and intend to contest it vigorously, we can give no assurance that an adverse outcome in this suit or others that may occur in the future would not have a material adverse effect on our consolidated results of operations, consolidated financial position and/or consolidated cash flow from operations, or would not require us to make material changes to our business practices. We periodically respond to subpoenas and requests for information from governmental agencies. To our knowledge, we are not a target or a potential subject of a criminal investigation. We cannot predict with certainty what the outcome of any of the foregoing might be or whether we may in the future become a target or potential target of an investigation or the subject of further inquiries or ultimately settlements with respect to the subject matter of these subpoenas. In addition to potential monetary liability arising from these suits and proceedings, from time to time we incur costs in providing documents to government agencies. Current pending claims and associated costs may be covered by our insurance, but certain other costs are not insured. There can be no assurance that such costs will not increase and/or continue to be material to our performance in the future.
 
We are largely dependent on one wholesale drug supplier and our results of operations could be materially adversely affected if we are not able to supply our pharmacies with adequate inventory for any reason, including the termination of our relationship with this key supplier.
 
In the event that we are unable to maintain adequate inventory in any of our pharmacies, we could experience an interruption in our ability to service customers. During the year ended December 31, 2012, we purchased approximately 92% of our inventory of prescription drugs from one wholesale drug supplier (H.D. Smith Wholesale Drug Co.). Although management believes we could obtain a majority of our inventory though another supplier at competitive prices and upon competitive payment terms if our relationship with this wholesale drug supplier is terminated, the termination of our relationship would be likely to adversely affect our business, prospects, financial condition and results of operations.
 
Because we are dependent on third-party payors, our business is volatile and there is an increased risk of loss of your investment.
 
Nearly all of our pharmacy sales are to customers whose medications were covered by health benefit plans and other third party payors. Health benefit plans include insurance companies, governmental health programs, workers’ compensation, self-funded ERISA plans, health maintenance organizations, health indemnity insurance, and other similar plans. In general, a health benefit plan agrees to pay for all or a portion of a customer’s eligible prescription purchases. Any significant loss of third-party payor business for any reason could have a material adverse effect on our business and results of operations. These third-party payors could change how they reimburse us, without our prior approval, for the prescription drugs that we provide to their members. In December 2003, the Medicare Prescription Drug, Improvement and Modernization Act granted a prescription drug benefit to participants which has resulted in us being reimbursed for some prescription drugs at prices lower than our current reimbursement levels. There have been a number of recent proposals and enactments by various states to reduce Medicaid reimbursement levels in response to budget problems, some of which propose to reduce reimbursement levels in the applicable states significantly, and we expect other similar proposals in the future. If third-party payors reduce their reimbursement levels or if Medicare or Medicaid programs cover prescription drugs at lower reimbursement levels, our margins on these sales would be reduced, and the profitability of our business and our results of operations, financial condition or cash flows would be adversely affected. Additionally, there are no guarantees that health benefit plans will contract with our pharmacies.
 
 
 
 
 
 
 
 
 
 
 
Continuing government and private efforts to contain healthcare costs may reduce our future revenue.
 
We could be adversely affected by the continuing efforts of government and private payors to contain healthcare costs. To reduce healthcare costs, payors seek to lower reimbursement rates, limit the scope of covered services and negotiate reduced or capped pricing arrangements. While many of the proposed policy changes would require congressional approval to implement, we cannot assure you that reimbursement payments under governmental and private third party payer programs will remain at levels comparable to present levels or will be sufficient to cover the costs allocable to patients eligible for reimbursement under these programs. Any changes that lower reimbursement rates under Medicare, Medicaid or private pay programs could result in a substantial reduction in our net operating revenues. Our operating margins may continue to be under pressure because of deterioration in reimbursement, changes in payer mix and growth in operating expenses in excess of increases, if any, in payments by third party payors.
 
The changing U.S. healthcare industry and increasing enforcement environment may negatively impact our business.
 
In recent years, the healthcare industry has undergone significant changes in an effort to reduce costs and government spending. These changes include an increased reliance on managed care and cuts in Medicare funding.
 
We expect the healthcare industry to continue to change significantly in the future. Some of these potential changes, such as a reduction in governmental support of healthcare services or adverse changes in legislation or regulations governing prescription drug pricing or mandated benefits, may cause healthcare payors to reduce the price they are willing to pay for pharmaceutical drugs. If we are unable to adjust to changes in the healthcare environment, it could have a material adverse effect on our financial position, results of operations and liquidity.
 
Further, both federal and state government agencies have increased their focus on and coordination of civil and criminal enforcement efforts in the healthcare area. The OIG and the U.S. Department of Justice have, from time to time, established national enforcement initiatives, targeting all providers of a particular type, that focus on specific billing practices or other suspected areas of abuse. In addition, under the federal False Claims Act, private parties have the right to bring “qui tam” whistleblower lawsuits against companies that submit false claims for payments to the government. A number of states have adopted similar state whistleblower and false claims provisions.
 
We are subject to increased costs and regulatory scrutiny relating to us carrying a larger amount of Schedule II drugs in inventory than most other pharmacies.
 
Because our business model focuses on servicing chronic pain patients, we carry a larger amount of Schedule II drugs in inventory than most other pharmacies.  Schedule II drugs, considered narcotics by the United States Drug Enforcement Administration (“DEA”), are the most addictive and considered to present the highest risk of abuse.  For this reason, Schedule II drugs are highly regulated by the DEA such regulations are more stringent than regulations impacting Schedule III and IV drugs.  The manufacture, shipment, storage, sale and use of controlled substances are subject to a high degree of regulation, including security, record-keeping and reporting obligations enforced by the DEA. This high degree of regulation associated with our sale of Schedule II drugs can result in significant regulatory costs in order to comply with the required regulations and also result in increased acquisition costs, which may reduce our profit margin and have a material adverse effect on our business, operating results and financial condition.
 
Changes in Medicare Part D and current and future regulations promulgated thereunder could adversely affect our revenue and impose increased costs.
 
The Medicare Prescription Drug Improvement and Modernization Act of 2003 ("MMA") included a major expansion of the Medicare program with the addition of a prescription drug benefit under the new Medicare Part D program. The continued impact of these regulations depends upon a variety of factors, including our ongoing relationships with the Part D Plans and the patient mix of our customers. Future modifications to the Medicare Part D program may reduce revenue and impose additional costs to our industry. In addition, we cannot assure you that Medicare Part D and the current and future regulations promulgated under Medicare Part D will not have a material adverse effect on our institutional pharmacy business.

 
 
 
 
 
 
 
 
If we fail to comply with complex and rapidly evolving laws and regulations, we could suffer penalties or be unable to operate our business.
 
We are subject to numerous federal and state regulations. Each of our pharmacy locations must be licensed by the state government. The licensing requirements vary from state to state. An additional registration certificate must be granted by the DEA, and, in some states, a separate controlled substance license must be obtained to dispense Class II drugs. In addition, pharmacies selling Class II drugs are required to maintain extensive records and often report information to state agencies. If we fail to comply with existing or future laws and regulations, we could suffer substantial civil or criminal penalties, including the loss of our licenses to operate our pharmacies and our ability to participate in federal and state healthcare programs. As a consequence of the severe penalties we could face, we must devote significant operational and managerial resources to complying with these laws and regulations. Although we believe that we are substantially compliant with all existing statutes and regulations applicable to our business, different interpretations and enforcement policies of these laws and regulations could subject our current practices to allegations of impropriety or illegality, or could require us to make significant changes to our operations. In addition, we cannot predict the impact of future legislation and regulatory changes on our business or assure that we will be able to obtain or maintain the regulatory approvals required to operate our business.
 
If we fail to comply with Medicare and Medicaid regulations, including the federal anti-kickback statute, we may be subjected to penalties or loss of eligibility to participate in these programs.
 
The Medicare and Medicaid programs are highly regulated. These programs are also subject to frequent and substantial changes. If we fail to comply with applicable reimbursement laws and regulations, whether purposely or inadvertently, our reimbursement under these programs could be curtailed or reduced or we could become ineligible to continue to participate in these programs. Federal or state governments may also impose other penalties on us for failure to comply with the applicable reimbursement regulations.
 
Among these laws is the federal anti-kickback statute. This statute prohibits anyone from knowingly and willfully soliciting, receiving, offering or paying any remuneration with the intent to induce a referral, or to arrange for the referral or order of, services or items payable under a federal healthcare program. Courts have interpreted this statute broadly. Violations of the anti-kickback statute may be punished by a criminal fine of up to $25,000 for each violation or imprisonment, civil money penalties of up to $50,000 per violation and damages of up to three times the total amount of the remuneration and/or exclusion from participation in federal health care programs, including Medicare and Medicaid. This law impacts the relationships that we may have with potential referral sources. We have relationships with a variety of potential referral sources, including physicians. The Office of Inspector General (“OIG”) at the U.S. Department of Health and Human Services (“HHS”), or OIG, among other regulatory agencies, is responsible for identifying and eliminating fraud, abuse or waste. The OIG carries out this responsibility through a nationwide program of audits, investigations and inspections. The OIG has promulgated safe harbor regulations that outline practices that are deemed protected from prosecution under the anti-kickback statute. While we endeavor to comply with the applicable safe harbors, certain of our current arrangements may not qualify for safe harbor protection. Failure to meet a safe harbor does not mean that the arrangement necessarily violates the anti-kickback statute, but may subject the arrangement to greater scrutiny. It cannot be assured that practices outside of a safe harbor will not be found to violate the anti-kickback statute.
 
The anti-kickback statute and similar state laws and regulations are expansive. We do not always have the benefit of significant regulatory or judicial interpretation of these laws and regulations. In the future, different interpretations or enforcement of these laws and regulations could subject our current or past practices to allegations of impropriety or illegality, or could require us to make changes in our pharmacies, personnel, services and operating expenses. A determination that we have violated these laws, or the public disclosure that we are being investigated for possible violations of these laws, could have a material adverse effect on our business, financial condition, results of operations or prospects and our business reputation could suffer significantly. If we fail to comply with the anti-kickback statute or other applicable laws and regulations, we could be subjected to liabilities, including criminal penalties, civil penalties (including the loss of our licenses to operate one or more pharmacies), and exclusion of one or more pharmacies from participation in the Medicare, Medicaid and other federal and state health care programs. In addition, we are unable to predict whether other legislation or regulations at the federal or state level will be adopted, what form such legislation or regulations may take or their impact.
 
Federal and state medical privacy regulations may increase the costs of operations and expose us to civil and criminal sanctions.
 
We must comply with extensive federal and state requirements regarding the transmission and retention of health information. The Health Insurance Portability and Accountability Act of 1996 and its implementing regulations, referred to as HIPAA, was enacted to ensure that employees can retain and at times transfer their health insurance when they change jobs, to enhance the privacy and security of personal health information and to simplify healthcare administrative processes. HIPAA requires the adoption of standards for the exchange of electronic health information. Failure to comply with HIPAA could result in fines and penalties that could have a material adverse effect on our results of operations, financial condition, and liquidity.
 
 
 
 
 
 
 
 

Unexpected safety or efficacy concerns may arise from pharmaceutical products.
 
Unexpected safety or efficacy concerns can arise with respect to pharmaceutical drugs dispensed at our pharmacies, whether or not scientifically justified, leading to product recalls, withdrawals or declining sales. If we fail to or do not promptly withdraw pharmaceutical drugs upon a recall by a drug manufacturer, our business and results of operations could be negatively impacted.
 
Prescription volumes may decline, and our net revenues and ability to generate earnings may be negatively impacted, if products are withdrawn from the market or if increased safety risk profiles of specific drugs result in utilization decreases.
 
We dispense significant volumes of drugs from our pharmacies. These volumes are the basis for our net revenues. When increased safety risk profiles of specific drugs or classes of drugs result in utilization decreases, physicians may cease writing or reduce the numbers of prescriptions written for these drugs. Additionally, negative press regarding drugs with higher safety risk profiles may result in reduced consumer demand for such drugs. On occasion, products are withdrawn by their manufacturers. In cases where there are no acceptable prescription drug equivalents or alternatives for these prescription drugs, our volumes, net revenues, profitability and cash flows may decline.
 
Certain risks are inherent in providing pharmacy services; our insurance may not be adequate to cover any claims against us.
 
Pharmacies are exposed to risks inherent in the packaging and distribution of pharmaceutical products, such as with respect to improper filling of prescriptions, labeling of prescriptions, adequacy of warnings, unintentional distribution of counterfeit drugs and expiration of drugs. In addition, federal and state laws that require our pharmacists to offer counseling, without additional charge, to their customers about medication, dosage, delivery systems, common side effects and other information the pharmacists deem significant can impact our business. Our pharmacists may also have a duty to warn customers regarding any potential negative effects of a prescription drug if the warning could reduce or eliminate these effects. Although we maintain professional liability insurance and an umbrella policy, from time to time, claims may result in the payment of significant amounts, some portions of which may not be funded by insurance.  Our current professional liability insurance coverage is $2 million per occurrence and $4 million in annual aggregate.  In addition, we carry an additional umbrella policy for coverage up to an additional $4 million in the aggregate. We cannot assure you that the coverage limits under our insurance programs will be adequate to protect us against future claims, or that we will be able to maintain this insurance on acceptable terms in the future. Our results of operations, financial condition or cash flows may be adversely affected if in the future our insurance coverage proves to be inadequate or unavailable or there is an increase in liability for which we self-insure or we suffer reputational harm.
 
Legal and regulatory changes reducing reimbursement rates for pharmaceuticals may reduce our gross profit.
 
Our own gross profit margins may be adversely affected by laws and regulations reducing reimbursement rates and charges. Our revenues are determined by a number of factors, including the mix of pharmaceuticals dispensed, whether the drugs are brand or generic and the rates of reimbursement among payors. Changes in the payor mix among private pay, Medicare and Medicaid can also significantly affect our earnings and cash flow.
 
If competition increases, our ability to attract and retain customers or expand our business could be impaired.
 
We face competition with local, regional and national companies, including other drugstore chains, independently owned drugstores and mail order pharmacies.  Competition in this industry is intense primarily because national pharmacies including Walgreens and CVS Pharmacy have expanded significantly.  Prescription drugs are now offered at a variety of retail establishments. Supermarkets and discount stores now maintain retail pharmacies onsite as a part of a business plan to provide consumers with all of their retail needs at one location. Many of these retail pharmacies rely substantially on the sale of non-prescription drugs or health and beauty related products to generate revenue. Our management is unaware of any company that operates pharmacies in the United States that exclusively dispense pharmaceutical products to patients who require medication for chronic pain management. Our business, prospects, financial condition, and results of operations could be negatively impacted if chain retail pharmacies revise their business model to focus on dispensing pharmaceutical products to patients who require medication for chronic pain management. We may not be able to effectively compete against them because our existing and potential competitors may have financial and other resources that are superior to ours. We cannot assure you that we will be able to continue to compete effectively in our market or increase our sales volume in response to further increased competition. In addition, we may be at a competitive disadvantage because we are more highly leveraged than our competitors. If we are unable to compete effectively with our competition, we will not be able to attract and retain business resulting in a loss of business and potential discontinuation of operations.
 
 
 
 
 
 
- 10 -

 
 

 
A significant disruption in our computer systems or a cyber security breach could adversely affect our operations.
 
We rely extensively on our computer systems to manage our ordering, pricing, point-of-sale, inventory replenishment and other processes. Our systems are subject to damage or interruption from power outages, computer and telecommunications failures, computer viruses, cyber security breaches, vandalism, severe weather conditions, catastrophic events and human error, and our disaster recovery planning cannot account for all eventualities. If our systems are damaged, fail to function properly or otherwise become unavailable, we may incur substantial costs to repair or replace them, and may experience loss of critical data and interruptions or delays in our ability to perform critical functions, which could adversely affect our business and results of operations. Any compromise of our security could also result in a violation of applicable privacy and other laws, significant legal and financial exposure, damage to our reputation, loss or misuse of the information and a loss of confidence in our security measures, which could harm our business.
 
Our ability to conduct operations depends on the security and stability of our technology infrastructure as well as the effectiveness of, and our ability to execute, business continuity plans across our operations. A failure in the security of our technology infrastructure or a significant disruption in service within our operations could materially adversely affect our business, the results of our operations and our financial position.
 
We maintain, and are dependent on, a technology infrastructure platform that is essential for many aspects of our business operations. It is imperative that we securely store and transmit confidential data, including personal health information, while maintaining the integrity of our confidential information. We have designed our technology infrastructure platform to protect against failures in security and service disruption. However, any failure to protect against a security breach or a disruption in service could materially adversely impact our business operations and our financial results. Our technology infrastructure platform requires an ongoing commitment of significant resources to maintain and enhance systems in order to keep pace with continuing changes as well as evolving industry and regulatory standards. In addition, we may from time to time obtain significant portions of our systems-related or other services or facilities from independent third parties, which may make our operations vulnerable to such third parties’ failure to adequately perform. In the event we or our vendors experience malfunctions in business processes, breaches of information systems, failure to maintain effective and up-to-date information systems or unauthorized or non-compliant actions by any individual, this could disrupt our business operations or impact patient safety, result in customer and member disputes, damage our reputation, expose us to risk of loss, litigation or regulatory violations, increase administrative expenses or lead to other adverse consequences.
 
We operate dispensing pharmacies and corporate facilities that depend on the security and stability of technology infrastructure. Any service disruption at any of these facilities due to failure or disruption of technology, malfunction of business process, disaster or catastrophic event could, temporarily or indefinitely, significantly reduce, or partially or totally eliminate our ability to process and dispense prescriptions and provide products and services to our clients and members. Any such service disruption at these facilities or to this infrastructure could have a material adverse effect on our business operations and our financial results.
 
Our failure to effectively manage new pharmacy openings could lower our sales and profitability.
 
Our strategic plan is largely dependent upon securing additional financing and opening new pharmacies and operating them profitably. Our ability to open new pharmacies and operate them profitably depends upon a number of factors, some of which may be beyond our control. These factors include:
 
    
the ability to identify new pharmacy locations, negotiate suitable leases and build out the pharmacies in a timely and cost efficient manner;
●    
the ability to hire and train skilled pharmacists and other employees;
●    
the ability to integrate new pharmacies into our existing operations and leverage existing infrastructure; and
●    
the ability to increase sales at new pharmacies locations.
 
A failure to manage new pharmacy openings in a timely and cost efficient manner would adversely affect our results of operations, financial condition and cash flows.
 
 
 
 

 
 
 
- 11 -

 
 
 
 
 
We will not be able to compete effectively if we are unable to attract, hire and retain qualified pharmacists.
 
There is a nationwide shortage of qualified pharmacists. We current employ five pharmacists, one pharmacist at each operating pharmacy. Although we have not experienced any difficulty recruiting pharmacists in the past, we may experience difficulty attracting, hiring and retaining qualified pharmacists in the future. If we are unable to attract, hire and retain enough qualified pharmacists, our business, prospects, financial condition, and results of operations could be adversely affected.
 
We will incur increased costs as a result of being a public reporting company.
 
As a public reporting company, we face increased legal, accounting, administrative and other costs and expenses as a public reporting company that we do not incur as a private company.  The Sarbanes-Oxley Act of 2002, including the requirements of Section 404, as well as new rules and regulations subsequently implemented by the Securities and Exchange Commission and the Public Company Accounting Oversight Board impose additional reporting and other obligations on public reporting companies. Compliance with these public company requirements increases our costs and makes some activities more time-consuming. A number of those requirements require us to carry out activities we have not done recently or at all. For example, we will adopt new internal controls and disclosure controls and procedures.  In addition, we incur additional expenses associated with our Securities and Exchange Commission reporting requirements.  For example, under Section 404 of the Sarbanes-Oxley Act, we will need to document and test our internal control procedures and our management will need to assess and report on our internal control over financial reporting. Furthermore, if we identify any issues in complying with those requirements (for example, if we or our accountants identify a material weakness or significant deficiency in our internal control over financial reporting), we could incur additional costs rectifying those issues, and the existence of those issues could adversely affect us, our reputation or investor perceptions of us. It also could become more difficult for us to attract and retain qualified persons to serve on our board of directors or as executive officers. Additional reporting and other obligations imposed on us by these rules and regulations has increased our legal and financial compliance costs and the costs of our related legal, accounting and administrative activities significantly.  Management estimates that compliance with the Exchange Act reporting requirements as a reporting company will cost in excess of $100,000 annually.  Given our current financial resources, these additional compliance costs could have a material adverse impact on our financial position and ability to achieve profitable results. These increased costs require us to divert money that we could otherwise use to expand our business and achieve our strategic objectives.
 
The health of the economy in general and in the markets we serve could adversely affect our business and our financial results.
 
Our business is affected by the economy in general, including changes that could affect drug utilization trends, resulting in an adverse effect on our business and financial results. Although a recovery might be underway, it is possible that a worsening of the economic environment will cause decline in drug utilization, and dampen demand for pharmaceutical drugs. If this were to occur, our business and financial results could be adversely affected.
 
Risk Factors Relating to this Offering of Our Common Stock
 
Our debenture holders and preferred stockholders would have priority in distributions over our common stockholders following a liquidation event affecting the company. As a result, in the event of a liquidation event, our common stockholders would receive distributions only after priority distributions are paid and may receive nothing in liquidation.
 
In the event of any Liquidation (as such term is defined in our Certificate of Designation of Series A, B and C Convertible Preferred Stock), the holders of our outstanding Series A, Series B and Series C Convertible Preferred Stock (collectively, “Preferred Stock”) would be entitled to a liquidation preference payment of $1,000 per share of Preferred Stock prior and in preference to any payment to holders of the Common Stock.  As a result, our Preferred Stock has an aggregate liquidation preference of approximately $7,477,000 .  Any proceeds after payment of the liquidation preference payment shall be paid pro rata to the holders of Preferred Stock and Common Stock on an as converted to Common Stock basis. The liquidation preference for our outstanding debentures ranks senior to our Preferred Stock and Common Stock.  As such, holders of Common Stock might receive nothing in liquidation, or receive much less than they would if there were no Preferred Stock outstanding.
 
We intend to secure additional funding in the future through issuances of securities and such additional funding may be dilutive to stockholders or impose operational restrictions.
 
We intend to secure additional funding in the future to help establish pharmacies and fund our operations through sales of shares of our common or preferred stock or securities convertible into shares of our common stock, as well as issuances of debt. Such additional financing may be dilutive to our stockholders, and debt financing, if available, may involve restrictive covenants which may limit our operating flexibility. If additional capital is raised through the issuances of shares of our common or preferred stock or securities convertible into shares of our common stock, the percentage ownership of existing stockholders will be reduced. These stockholders may experience additional dilution in net book value per share and any additional equity securities may have rights, preferences and privileges senior to those of the holders of our common stock.
 
 
 

 
 
- 12 -

 
 
 
 
If the selling stockholders sell a substantial number of shares all at once or in large blocks, the market price of our shares would most likely decline.
 
The selling stockholders may offer and sell up to 2,292,067 shares of our common stock through this prospectus.  Our common stock is presently quoted on the OTC Markets and any sale of shares at a price below the current market price at which the common stock is trading will cause that market price to decline.  Moreover, the offer or sale of a large number of shares at any price may cause the market price to fall.  We cannot predict the effect, if any, that future sales of shares of our common stock into the market, including those acquirable by the possible exercise of warrants for shares of common stock, will have on the market price of our common stock. Sales of substantial amounts of common stock, including shares issued upon the exercise of warrants and stock options for common stock, or the perception that such transactions could occur, may materially and adversely affect prevailing markets prices for our common stock.
 
Our principal stockholder currently has the ability to elect a majority of our directors and may have different interests than us or you in the future.
 
Even if all of the underlying shares of our common stock offered through this prospectus are issued and sold by the selling stockholders, Mosaic Capital Advisors, LLC (“Mosaic”) will beneficially own approximately 48.8 % of our outstanding common stock and will beneficially own 96.2% of our outstanding Series A Convertible Preferred Stock. So long as 35% of the authorized shares of Series A Preferred Stock are outstanding, the holders of outstanding shares of Series A Preferred Stock shall, voting together as a separate class, be entitled to elect four Directors to the Board.  Mosaic partially exercised this right by appointing  Messrs. Sheth, Bilodeau and Eagle to serve as directors.  As a result, Mosaic has the ability to exert control over our management and affairs and over matters requiring stockholder approval, including the election of a majority of our directors and approval of significant corporate transactions. In addition, this concentration of ownership may delay or prevent a change in our control and might affect the market price of our common stock, even when a change in control may be in the best interest of all stockholders. Furthermore, the interests of this concentration of ownership may not always coincide with our interests or the interests of other stockholders.
 
If we issue additional shares of preferred stock with superior rights than the common stock registered in this prospectus, it could result in a decrease in the value of our common stock and further delay or prevent a change in control of us.
 
Our board of directors is authorized to issue up to 5,000,000 shares of preferred stock.  As of May 31, 2013 , there were (i) 1,466 shares of Series A Preferred Stock issued and outstanding, which are convertible into 1,629,006 shares of common stock; (ii) 5,199  shares of Series B Preferred Stock issued and outstanding, which are convertible into 5,776,677 shares of common stock; and  (iii) 813 shares of Series C Preferred Stock issued and outstanding, which are convertible into 902,778 shares of common stock.  Our board of directors has the power to establish the dividend rates, liquidation preferences, voting rights, redemption and conversion terms and privileges with respect to any series of preferred stock. The issuance of any shares of preferred stock having rights superior to those of the common stock may result in a decrease in the value or market price of the common stock. Holders of preferred stock may have the right to receive dividends, preferences in liquidation and conversion rights. The issuance of preferred stock could, under certain circumstances, have the effect of delaying, deferring or preventing a change in control of us without further vote or action by the stockholders and may adversely affect the voting and other rights of the holders of common stock.
 
If we are unable to achieve net revenue milestones we will be required to issue additional common stock and common stock warrants resulting in additional dilution to our stockholders.
 
Our 2013 private placement is subject to certain “Make Whole” adjustments based on consolidated revenues for the fiscal year 2013.  The private placement terminated on May 30, 2013.  We completed sales of $860,000 in securities per the private placement for a total of 1,323,093 common shares and 1,323,093 common stock warrants with an exercise price of $0.90 per share.  In the event that the minimum revenue milestone is not reached, the investors would receive a total of 2,150,000 common shares and 2,150,000 common stock warrants with an exercise price of $0.65 per share.
 
If we issue common stock at a price below the effective common stock price of previous issuances, we may be required to issue additional common stock and common stock warrants resulting in additional dilution to our stockholders.
 
All of the Company’s convertible notes and related warrants, preferred stock, and the common stock and related warrants issued in the 2013 private placement contain anti-dilution provisions that give the investors the right to equal price adjustments in the event of the issuance of stock below the current price of the existing investor.   The investors also have the right to waive their respective anti-dilution rights.  In the event that the Company is required to issue shares below the effective price and is unable to obtain waivers, the issuance of additional common stock and warrants will be required resulting in additional dilution to existing stockholders.
 

 
 
 
 
 
- 13 -

 
 
 
 
Trading on the OTC Markets is volatile and sporadic, which could depress the market price of our common stock and make it difficult for our stockholders to resell their shares.

 Our common stock is quoted on the OTC Markets.  Trading in stock quoted on the OTC Markets is often thin and characterized by wide fluctuations in trading prices, due to many factors, some of which may have little to do with our operations or business prospects.  This volatility could depress the market price of our common stock for reasons unrelated to operating performance.  Moreover, the OTC Markets is not a stock exchange, and trading of securities on the OTC Markets is often more sporadic than the trading of securities listed on a quotation system like NASDAQ or a stock exchange like NYSE or Amex.  These factors may result in investors having difficulty reselling any shares of our common stock.
 
Because our common stock is quoted and traded on the OTC Markets, short selling could increase the volatility of our stock price.

 Short selling occurs when a person sells shares of stock which the person does not yet own and promises to buy stock in the future to cover the sale.  The general objective of the person selling the shares short is to make a profit by buying the shares later, at a lower price, to cover the sale.  Significant amounts of short selling, or the perception that a significant amount of short sales could occur, could depress the market price of our common stock. In contrast, purchases to cover a short position may have the effect of preventing or retarding a decline in the market price of our common stock, and together with the imposition of the penalty bid, may stabilize, maintain or otherwise affect the market price of our common stock.  As a result, the price of our common stock may be higher than the price that otherwise might exist in the open market.  If these activities are commenced, they may be discontinued at any time.  These transactions may be effected on the OTC Markets or any other available markets or exchanges.  Such short selling if it were to occur could impact the value of our stock in an extreme and volatile manner to the detriment of our shareholders.
 
Our stock price is likely to be highly volatile because of several factors, including a limited public float.
 
The market price of our common stock has been volatile in the past and is likely to be highly volatile in the future because there has been a relatively thin trading market for our stock, which causes trades of small blocks of stock to have a significant impact on our stock price.  You may not be able to resell shares of our common stock following periods of volatility because of the market’s adverse reaction to volatility.
 
Other factors that could cause such volatility may include, among other things:
 
  
actual or anticipated fluctuations in our operating results;
●  
the absence of securities analysts covering us and distributing research and recommendations about us;
●  
we may have a low trading volume for a number of reasons, including that a large portion of our stock is closely held;
●  
overall stock market fluctuations;
●  
announcements concerning our business or those of our competitors;
●  
actual or perceived limitations on our ability to raise capital when we require it, and to raise such capital on favorable terms;
●  
conditions or trends in the industry;
●  
litigation;
●  
changes in market valuations of other similar companies;
●  
future sales of common stock;
●  
departure of key personnel or failure to hire key personnel; and
●  
general market conditions.
 
Any of these factors could have a significant and adverse impact on the market price of our common stock. In addition, the stock market in general has at times experienced extreme volatility and rapid decline that has often been unrelated or disproportionate to the operating performance of particular companies. These broad market fluctuations may adversely affect the trading price of our common stock, regardless of our actual operating performance.
 
 
 

 
 
- 14 -

 
 
 
 
FINRA (“Financial Industry Regulatory Authority”) sales practice requirements may limit a stockholder’s ability to buy and sell our stock.
 
FINRA has adopted rules that require that in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending speculative low priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer’s financial status, tax status, investment objectives and other information. Under interpretations of these rules, FINRA believes that there is a high probability that speculative low priced securities will not be suitable for at least some customers. FINRA requirements make it more difficult for broker-dealers to recommend that their customers buy our common stock, which may have the effect of reducing the level of trading activity and liquidity of our common stock. Further, many brokers charge higher transactional fees for penny stock transactions. As a result, fewer broker-dealers may be willing to make a market in our common stock, which may limit your ability to buy and sell our stock.
 
Because our common stock is quoted on the OTC Markets and is subject to the “Penny Stock” rules, investors may have trouble reselling their shares.
 
Broker-dealer practices in connection with transactions in “penny stocks” are regulated by penny stock rules adopted by the Securities and Exchange Commission. Penny stocks generally are equity securities with a price of less than $5.00 (other than securities registered on some national securities exchanges or quoted on the over-the-counter markets). The penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document that provides information about penny stocks and the nature and level of risks in the penny stock market. The broker-dealer also must provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson in the transaction, and, if the broker-dealer is the sole market maker, the broker-dealer must disclose this fact and the broker-dealer’s presumed control over the market, and monthly account statements showing the market value of each penny stock held in the customer’s account. In addition, broker-dealers who sell these securities to persons other than established customers and “accredited investors” must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser’s written agreement to the transaction.  Should a broker-dealer be required to provide the above disclosures or fail to deliver such disclosures on the execution of any transaction involving a penny stock in violation of federal or state securities laws, you may be able to cancel your purchase and get your money back. In addition, if the stocks are sold in a fraudulent manner, you may be able to sue the persons and firms that caused the fraud for damages. If you have signed an arbitration agreement, however, you may have to pursue your claim through arbitration.  Consequently, these requirements may have the effect of reducing the level of trading activity, if any, in the secondary market for a security subject to the penny stock rules, and investors in our common stock may find it difficult to sell their shares.
 
If we fail to maintain an effective system of internal controls, we may not be able to accurately report our financial results or prevent fraud resulting in current and potential stockholders losing confidence in our financial reporting.
 
Effective internal controls are necessary for us to provide reliable financials reports and effectively prevent fraud. If we cannot provide reliable financial reports or prevent fraud, our operating results could be harmed. We have during fiscal 2008 discovered, and may in the future discover, areas of our internal controls that need improvement. During fiscal 2008, our internal controls need improvement and the primary contributing factors to the need for such improvement  were that we did not maintain a sufficient complement of personnel with a level of knowledge of our accounting records and technical competence to ensure proper application of U.S. generally accepted accounting principles and we did not maintain sufficient written policies and procedures, and support.  We remediate these issues by retaining new personnel with the requisite level of knowledge and experience, including Mr. Brett Cormier as our Chief Financial Officer, and developing and implementing appropriate written policies and procedures.  Any failure to implement required new or improved controls, or difficulties encountered in their implementation, could harm our operating results or cause us to fail to meet our reporting obligations. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our stock.
 
We have never paid dividends and have no plans to in the future.
 
Holders of shares of our common stock are entitled to receive such dividends as may be declared by our board of directors. To date, we have paid no cash dividends on our shares of common stock and we do not expect to pay cash dividends on our common stock in the foreseeable future. We intend to retain future earnings, if any, to provide funds for operations of our business. Therefore, any return investors in our common stock may have will be in the form of appreciation, if any, in the market value of their shares of common stock. See “Dividend Policy.”
 
We provide indemnification of our officers and directors and we may have limited recourse against these individuals.
 
Our Amended and Restated Articles of Incorporation and Bylaws contain broad indemnification and liability limiting provisions regarding our officers and directors, including the limitation of liability for certain violations of fiduciary duties. We therefore will have only limited recourse against these individuals.
 
 
 
 
 
 
- 15 -

 
 
 
 
 
The selling stockholders are selling all of the shares of common stock being offered pursuant to this prospectus. See “Selling Stockholders”.  We will not receive any proceeds from the sale of shares of our common stock by the selling stockholders in this offering. Any proceeds received by us in connection with the exercise of warrants to purchase shares of our common stock by the selling stockholders in connection with this offering will be used for general corporate purposes.
 
 
We have not paid any cash dividends on our common stock and do not currently anticipate paying cash dividends in the foreseeable future. The agreements into which we may enter in the future, including indebtedness, may impose limitations on our ability to pay dividends or make other distributions on our capital stock. The payment of dividends is prohibited without the consent of the holders of a majority of our Series A and Series C Preferred Stock.  If the holders of our Series A and Series C Preferred Stock approve, future dividends on our common stock, if any, will be at the discretion of our board of directors and will depend on, among other things, our results of operations, cash requirements and surplus, financial condition, contractual restrictions and other factors that our board of directors may deem relevant. We intend to retain future earnings, if any, for reinvestment in the development and expansion of our business.
 
 
The following table presents our capitalization as of March 31, 2013 . You should read the following table in conjunction with “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our financial statements and related notes included elsewhere in this prospectus.
 
   
March 31, 2013
 
       
Total Current Debt, net of discount
 
$
6,456,891
 
Long-term Debt, net of discount
   
716,629
 
Total Debt, net of discount
   
7,173,520
 
         
Stockholders’ Deficit
       
         
Preferred Stock, par value $0.001 per share; 5,000,000 shares authorized; 2,830 shares
designated to Series A convertible, 7,745 shares designated to Series B convertible,
813 shares designated to Series C convertible
       
         
Series A convertible preferred stock; par value $0.001 per share; 2,830 shares
authorized, 1,466 shares issued and outstanding.
   
1
 
Series C convertible preferred stock; par value $0.001 per share; 813 shares
authorized, 813 shares issued and outstanding.
   
1
 
Series B convertible preferred stock; par value $0.001 per share; 7,745 shares authorized,
5,384 shares issued and outstanding.
   
5
 
Common stock, par value $0.001 per share; 35,000,000 shares authorized,
5,627,267 common shares issued and outstanding.
   
5,628
 
Additional paid-in-capital, net
   
36,958,776
 
Accumulated deficit
   
(44,196,884
)
Total stockholders’ deficit
   
(7,232,473
)
         
Total deficit
 
$
(58,953
)
 
 
 
 
 
 
 
 
- 16 -

 
 
 
 
 
Overview and Pharmacy Business
 
We were organized as a Nevada corporation on October 22, 1999 under the name Surforama.com, Inc. and previously operated under the name eRXSYS, Inc.  We changed our name to Assured Pharmacy, Inc. in October 2005.  Since May 2003, we have been engaged in the business of establishing and operating pharmacies that specialize in dispensing highly regulated pain medication for chronic pain management.  Because our focus is on dispensing medication, we typically will not keep in inventory non-prescription drugs, or health and beauty related products, such as walking canes, bandages and shampoo. We primarily derive our revenue from the sale of prescription medications.   The majority of our business is derived from repeat business from our customers.
 
Our pharmacies maintain a variety of different drug classes, known as Schedule II, Schedule III, and Schedule IV drugs, which vary in degrees of addictiveness.  Schedule II drugs considered narcotics by the United States Drug Enforcement Administration (“DEA”), are the most addictive; hence, they are highly regulated by the DEA and are required to be segregated and secured in a separate cabinet.  Schedule III and Schedule IV drugs are less addictive and are less regulated.  Because our business model focuses on servicing pain management physicians and their chronic pain patients, we carry in inventory a larger amount of Schedule II drugs than most other pharmacies.
 
We currently have four operating pharmacies, each of which are wholly owned through a subsidiary. The opening date and locations of our pharmacies are as follows:
 
Location
 
Opening Date
 
Riverside, California
 
June 10, 2004
Kirkland, Washington
 
August 11, 2004
Gresham, Oregon
 
January 26, 2007
Leawood, Kansas
 
November 28, 2011

In February 2004, we entered into an agreement with TAPG, L.L.C., a Louisiana limited liability company (“TAPG”), for the purpose of operating up to five pharmacies and incorporated Assured Pharmacies Northwest, Inc. (“APN”), formerly known as Safescript Northwest, Inc., to operate these pharmacies.  Under this agreement, TAPG was required to contribute financing in the amount of $335,000 for each pharmacy and we contributed certain intellectual property rights and sales and marketing services.  APN operates the pharmacy in Kirkland, Washington and previously operated another pharmacy in Portland, Oregon which was closed in December 2008 and consolidated with the operations of our Gresham, Oregon pharmacy.  We initially owned 75% of APN’s outstanding capital stock and TAPG owned the remaining 25%. From time to time, we advanced interest-free loans to sustain operations at the pharmacies operated by APN.  In March 2006, the outstanding principal balance on these loans were converted into APN capital stock resulting in us increasing our ownership interest in APN from 75% to 94.8%, which resulted in TAPG’s ownership in APN being diluted to own the remaining 5.2% of APN’s outstanding capital stock.  In June 2011, we acquired all of the outstanding capital stock of APN held by TAPG pursuant to the terms of a Stock Purchase Agreement dated as June 30, 2011.  Pursuant to this agreement, we issued TAPG 300,000 restricted shares of our common stock and TAPG agreed to cancel $17,758 in principal and interest we owed to TAPG.  As a result of this transaction, APN became our wholly owned subsidiary.
 
In April 2003, we entered into an agreement with TPG, L.L.C., a Louisiana limited liability company (“TPG”), for the purpose of funding the establishment of and operating up to fifty pharmacies and incorporated Assured Pharmacies, Inc. (“API”) to operate these pharmacies.   We owned 51% of API’s outstanding capital stock and TPG owned the remaining 49%.  API operated the pharmacies in Santa Ana and Riverside, California.  In December 2012, we consolidated the operations of the Santa Ana pharmacy into our Riverside pharmacy.  We entered into a Purchase Agreement with TPG and acquired all of the outstanding capital stock of API held by TPG for the purchase price of $460,000 in cash and the issuance of 278 restricted shares of our common stock. 
 
 
 
 
 
 
- 17 -

 
 
 
 
As a result of this transaction, API also became our wholly owned subsidiary.  The cash component of the purchase price is payable in monthly installments over time.  As of May 31, 2013, we had paid TPG an aggregate of $332,500 including principal and interest and certain other obligations to TPG under the Purchase Agreement.  Due to our current financial condition, we did not make the required monthly installment payment of $10,000 starting in September 15, 2012 through May 15, 2013 and may be unable to make the delinquent payments or the final payment due to TPG which includes principal and interest on or before July 15, 2013.  As of May 31, 2013, we owe TPG $242,873 plus all accumulated accrued interest.  If we remain unable to fulfill our obligations to TPG under the Purchase Agreement, we will attempt to restructure and extend the terms of payments due to TPG, but can provide no assurance we will be able to do so on acceptable terms or even at all.  In order to secure our obligations under the Purchase Agreement, TPG holds a security interest in the shares of API capital stock acquired by us under the Purchase Agreement.  If TPG should demand payment and we are unable to renegotiate the terms for our outstanding obligations to TPG under the Purchase Agreement, TPG could declare us in default and may seize the shares of API capital stock acquired by us under the Purchase Agreement, which would result in API no longer being a wholly owned subsidiary and have a material adverse effect on our business, operating results and financial condition.  TPG has not issued a notice of default relating to our failure to make the monthly installment payments required under the Purchase Agreement.
 
Our pharmacy in Gresham, Oregon is operated by Assured Pharmacy Gresham, Inc, and our pharmacy in Leawood, Kansas is operated by Assured Pharmacy Kansas, Inc., each of which are wholly owned subsidiaries.
 
Market for Our Products and Services
 
We primarily dispense pharmaceutical drugs to patients who require medication for chronic pain management.  Our pharmacies maintain an inventory of highly regulated medication that is specifically tailored to the needs of our recurring customers.   This practice frequently enables our pharmacies to fill customers’ prescriptions from its existing inventory and decreases the wait time required to fill these prescriptions.  We believe our focus and familiarity with dispensing highly regulated medications better positions our pharmacists to understand the needs of our customers.
 
Principal Suppliers
 
We do not have any written supply agreements with any of our drug suppliers and all transactions are handled on a purchase order basis.  We purchased approximately 92% of our inventory of prescription drugs from one wholesale drug supplier (H.D. Smith Wholesale Drug Co.) during the fiscal year 2012.  Management believes that the wholesale pharmaceutical and non-pharmaceutical distribution industry is highly competitive because of the consolidation of the pharmacy industry and the practice of certain large pharmacy chains to purchase directly from product manufacturers. Although management believes we could obtain the majority of our inventory through other distributors at competitive prices and upon competitive payment terms if our relationship with our primary wholesale drug supplier was terminated, the termination of our relationship would be likely to adversely affect our business, prospects, financial condition and results of operation.
 
Customers and Third-Party Payors
 
In fiscal 2012, over 92 percent of our pharmacy sales were to customers covered by health care insurance plans, which typically contract with a third-party payor such as an insurance company, a prescription benefit management company, a governmental agency, workers’ compensation, a private employer, a health maintenance organization or other managed care provider.  The plan agrees to pay for all or a portion of a customer’s eligible prescription purchases sometimes at reduced reimbursement levels. Any significant loss of third-party payor business could have a material adverse effect on our business and results of operations.
 
Strategic Plan
 
Our plan is to develop a national footprint as a premier provider of pharmacy services to physicians and patients primarily in the treatment of chronic pain.  Our business model provides pharmacy services which are typically utilized by physicians for the risk management benefits of our model in this increasingly regulated industry due to prescription drug abuse and diversion.  Chronic pain patients typically utilize our services for the convenience, safety and specialization benefits.
 
We have developed and refined what we believe is a unique pharmacy service model for chronic pain patients that is capable of being scaled into a national chain.  We currently have four operating pharmacies, each of which is wholly owned through a subsidiary, and our plan is to develop three (3) additional pharmacies per year up to a total of twelve operating pharmacies.  We intend to finance this plan through equity and debt financing arrangements, increased sales and lower operating expenses, but there can be no assurance that such additional financing will be available to us on acceptable terms, or at all.
 
 
 
 
 
 
- 18 -

 
 

 
 
Over the past year, we have undertaken targeted actions to reduce certain costs relating to our corporate infrastructure and pharmacy operations, while still maintaining the specialized controls required for our industry.  These targeted actions include a reduction in the number of staff in our established four pharmacies and at the corporate level, a reduction in the cost of dispensing supplies due to a change in our supplier for these products and a decrease in investor relations expense due to the discontinuation of the use of an investor relations service firm.  Corporate infrastructure includes executive management, centralized support services, accounting, finance, information systems, human resources, payroll and compliance to support each pharmacy's operations.  Notwithstanding theses actions, our total operating expenses have increased and the costs to support our existing corporate infrastructure are significant when allocated over the operations of four pharmacies.
 
Management believes that our current corporate infrastructure can efficiently support our existing pharmacies and develop three additional new pharmacies per year up to total of fifteen operating pharmacies.  As a result, we believe that the implementation of our plan to open up to eight additional pharmacies will not require material additional corporate infrastructure.  Further, we expect that the opening of each new pharmacy will have a positive impact on our consolidated operating results within nine months from opening of the new pharmacy, but there can be no assurance that such positive results will occur.
 
The success of future pharmacy locations is highly dependent on the location of that particular pharmacy.  Future pharmacy locations, when established, will be selected based on criteria which include: i) the proximity to physician and medical facilities; ii) convenience of the particular location; iii) size and growth rate of the surrounding metropolitan area; iv) state and local tax rates; v) competitive business environment and vi) access to qualified personnel and the associated cost.  Management believes that the success of new pharmacies will be positively impacted by its research process and diligence in selecting new locations.
 
The foundation for our plan to increase sales at our existing four pharmacies is based on increasing our outreach program to physicians, more effectively communicating to them the risk management and service benefits that our business model provides and increasing our customer retention rate.  Presently, our customer retention rates are adversely impacted by our inability to purchase inventory necessary to fill every prescription we receive.  We believe that our customer retention rates can be strengthened by increasing our inventory levels and expanding our purchasing capacity with existing and new drug suppliers. Since the majority of our pharmacies’ operating expenses are fixed expenses, we expect any increase in revenue to have a positive impact or our consolidated operating results.  Management believes that our existing pharmacies can increase prescription production volume by as much as an additional 50% - 75% without incurring any significant additional operating expenses, but there can be no assurances in this regard.
 
The implementation of the foregoing plan to increase sales at our existing pharmacies and open additional pharmacies is dependent on our ability to obtain additional financing and improve our liquidity position.  If we are not able to secure additional financing, the implementation of our business plan will be delayed and our ability to expand and develop additional pharmacies will be impaired.  We are currently seeking up to $3.0 million in additional funding through equity financing arrangements in addition to the debt restructuring described below, but there can be no assurance that such additional financing will be available to us on acceptable terms, or at all.  Management has registered a class of our common stock under the Securities Exchange Act of 1934, as amended, and believes that filing periodic public reports with the SEC will enhance our ability to raise capital and under acceptable terms.
 
Our business is highly leveraged and the successful implementation of the foregoing plan necessitates that we reach an agreement with our existing debt holders to extend the maturity date of debt securities which came due in 2012.  As of March 31, 2013 , we had $844,948 in debt securities which were due in the year 2012, which included $500,000 in principal amount of unsecured convertible debentures.    We are attempting to extend the maturity date of all outstanding debt securities which were due in 2012, but can provide no assurance that the holders of such securities will agree to extend the maturity date on these securities on acceptable terms.  We are also discussing the possibility of these debt holders converting the securities into equity.  If our debt holders choose not to convert certain of these securities into equity, we will need to repay such debt, or reach an agreement with the debt holders to extend the terms thereof.  If we are forced to repay the debt, this need for funds would have a material adverse impact on our business operations, financial condition and prospects, would threaten our ability to operate as a going concern and may force us to seek bankruptcy protection.
 
 
 
 
 
 
 
 
 
- 19 -

 
 
 

Our lack of liquidity has resulted in us being significantly reliant on our drug suppliers for financing which has compromised our ability to negotiate more favorable pricing terms.   To the extent that we are successful in securing additional financing, we intend to allocate a portion of any proceeds we receive toward paying down our outstanding balance due with our primary drug supplier.  Management anticipates that reducing our dependence on our primary drug supplier for financing will enable us to secure more favorable pricing terms and minimize the resulting financing and interest fees we incur.  Management believes that drug pricing improvements of 100 to 200 basis points are possible in addition to the elimination of financing and interest fees from our primary drug supplier if we are successful in reducing or, to the extent possible, eliminating our purchase of drugs using supplier financing. In February 2013, the Company entered into a secured loan agreement with our primary wholesaler. Under the terms of this agreement, the Company received a one (1) year loan of $3,828,527 with an interest rate of 6.25% per annum, with interest payable monthly. Monthly payment requirements are $27,000 per month for four consecutive months, followed by four consecutive monthly principal reductions of $37,000, followed by three consecutive monthly in principal reductions of $42,000, with remaining principal and interest due February 1, 2014. The proceeds from the note were simultaneously exchanged for $3,534,793 in outstanding vendor invoices and $293,734 in outstanding secured note payable. The note is secured by all of the assets of the Company and its subsidiaries through UCC-1 filings in the states of Nevada and Louisiana.  As long as the Company is in compliance with the terms of the loan agreement, the Company will realize drug pricing improvements of 100 to 200 basis points in addition to the elimination of financing and interest fees associated with the trade payable.
 
We currently have approximately $1.0 million in gross receivables due from various workers’ compensation carriers in the State of California. These receivables are primarily related to worker’s compensation claims from insurance carriers for prescription medications dispensed to injured workers in the State of California.  The delay in payment typically arises due to monetary disputes between the claimant and the employer and/or the employer’s insurance carrier. The settlement period for such dispute cases can range from one year to ten years.  Management estimates the net realizable value of the other receivables to be approximately $195,000.   On April 1, 2010, we discontinued dispensing medication to California worker’s compensation customers whose claims could not be authorized and billed electronically.  This change was due to lower profit margins and cash flow constraints that are associated with the manual authorization and billing process.  We recently engaged a collection firm that specializes in the collection of these type of receivables to aggressively collect these past due receivables.  During the year ended December 31, 2012, our collection firm collected approximately $229,000 in past due balances resulting in approximately $136,000 in bad debt recoveries.  We expect that any recovery of these outstanding receivables will improve our overall operating cash flow, but we can make no assurances in this regard.
 
Management believes that the foregoing plan and outlined steps to improve our liquidity position will have a positive impact on our efforts to generate earnings and positive cash flow, but the implementation of such plan is dependent on our ability to secure additional financing and restructure our outstanding debt.  We can make no assurances in this regard.  In January 2013, we initiated a securities offering through a private placement for a minimum of 10 units of securities for a minimum of $250,000 and a maximum of 80 units for a maximum of $2,000,000 (subject to increase to as much as 100 units for $2,500,000 to cover  over-allotments, if any).  Each unit consists of (a) 38,462 shares of common stock, valued at $0.65 for $25,000 and (b) 38,462 warrants with an initial exercise price of $0.90 per share.  In the event only the minimum offering of 10 units are sold, the Company will issue an aggregate of 384,620 shares of common stock and 384,620 warrants in such units.  If the maximum offering of 80 units is sold, Assured will issue an aggregate of 3,076,960 shares of common stock and 3,076,960 warrants in such units.  The Company will pay the placement agent a cash commissions equal to 10% of the gross proceeds received by the Company in this offering and three year warrants to purchase that number of shares of common stock equal to 10% of the aggregate number of shares of common stock and warrant shares included in the units sold in the offering (615,392 shares if all 80 units are sold and 769,240 shares if the over-allotment is exercised in full). The outstanding common stock related to the private placement is subject to certain anti-dilution protection clauses which provide exercise price adjustments in the event that any common stock or common stock equivalents are issued at an effective price per share that is less than the exercise price per share.  The Company has also agreed that the 38,462 shares of common stock and the 38,462 warrants included in the units are subject to increase, and the $0.65 per share value and the $0.90 warrant exercise prices are subject to decrease, in each case based on the level of the Company’s consolidated net revenues that are derived during our 2013 fiscal year (the “Make-Whole Adjustments”).  Such Make-Whole Adjustments are as follows:
 
Share
Price
Warrant
Exercise Price
Adjusted Shares
per Unit
Adjusted Warrants
per Unit
Consolidated
2013 Revenues
$0.65
$0.90
None
None
$21,850,000 or above
$0.60
$0.85
41,667
41,667
From $20,700,000 to $21,849,999
$0.55
$0.80
45,455
45,455
From $19,550,000 to $20,699,999
$0.50
$0.75
50,000
50,000
From $18,400,000 to $19,549,999
$0.45
$0.70
55,556
55,556
From $17,250,000 to $18,399,999
$0.40
$0.65
62,500
62,500
Less than $17,250,000
 
 
 
 
 

 
 
- 20 -

 
 
 
 
 
Each warrant has a term of three years and may be exercised at an initial exercise price of $0.90 per warrant share, which exercise price is, in addition to the potential Make-Whole Adjustment, subject to certain weighted average and other anti-dilution adjustments as provided in the form of warrant.  The warrants may only be exercised for cash.  However, as provided in the Registration Rights Agreement (described below), after a date which shall be 180 days following the Final Closing Date, there will be a cashless exercise option available to the warrant holders at any time during which a registration statement providing for the resale of the warrant shares is not effective, unless the warrant shares may then be freely tradable without limitation pursuant to an exemption from the registration requirements under the Securities Act. Assuming completion of the $2,000,000 Maximum Offering, $650,000 of the net proceeds (after offering expenses) will be used to reduce our outstanding balance to our primary wholesale drug supplier; approximately $350,000 will be used to open our fifth pharmacy in Denver, Colorado; and the remaining net proceeds, estimated at approximately $750,000 will be used for working capital and general corporate purposes (including the repayment of certain debt obligations described below, and the potential opening of as many as two additional pharmacies in 2013 and 2014). The private placement is ongoing and will expire on May 30, 2013.
 
A consent and waiver was obtained from a holder of a majority of the Series A and C preferred stock and a waiver was obtained from the holders of a majority of the Series B preferred stock as required in the certificate of designation. A waiver was obtained from all convertible debenture holders that were required.  As part of the waivers, the Series A, B, and C preferred holders and 100 percent of the applicable convertible debenture holders agreed to waive anti-dilution adjustments which the consenting holder may be entitled under their respective agreements and accept a partial ratchet anti-dilution adjustment with a decrease in the conversion price to $0.90 per share of the Company securities for the private placement provided the minimum unit threshold was met.  The table below summarizes the impact of the $0.90 partial ratchet anti-dilution adjustment by security:

   
December 31, 2012
   
Adjusting
Anti-dilution
effect
   
Post Adjusted
Anti-dilution
effect
 
                   
Warrants
   
3,811,116
     
1,669,056
     
5,480,172
 
Stock options
   
1,840,556
     
-
     
1,840,556
 
Convertible notes
   
2,304,478
     
990,844
     
3,295,322
 
Series A Preferred
   
1,292,492
     
269,848
     
1,562,340
 
Series B Preferred
   
2,993,504
     
2,988,729
     
5,982,233
 
Series C Preferred
   
451,750
     
451,028
     
902,778
 
                         
     
12,693,896
     
6,369,505
     
19,063,401
 
 
 
 
 
 
 
 
 
- 21 -

 
 

 
 
 
From February 2013 through the expiration date of the private placement on May 30, 2013, the Company completed sales to eight accredited investors in the private placement for 34.4 common stock units for a total of 1,323,093 shares of common stock at an aggregate purchase price of $860,000 (before deducting expenses and fees related to the private placement) and warrants to purchase an aggregate of 1,323,093 with an initial exercise price of $0.90 per share.  The Company paid cash fees of $32,800 to the placement agent and is also obligated to issue 50,462 warrants with an exercise price of $0.90 and 50,462 warrants with an exercise price of $0.65 to the placement agent at a negotiated discount rate to the placement agent agreement terms.  The net proceeds of the initial closing of the private placement were used to pay down our outstanding balance with our primary wholesaler.  
 
In February and March 2013, the Company also issued a total of 60 shares of Series A Preferred at $1,000 per share for a total of $60,000 to Mosaic Private Equity Fund US, LP, a related party.  The net proceeds of the sale were used for general working capital purposes.
 
Competition
 
We face competition with local, regional and national companies, including other drugstore chains, independently owned drugstores and mail order pharmacies.  Competition in this industry is intense primarily because national pharmacies including Walgreens and CVS Pharmacy have expanded significantly and prescription drugs are now offered at a variety of retail establishments when traditionally prescription drugs were only provided at local pharmacies. Supermarkets and discount stores now maintain retail pharmacies onsite as a part of a business plan to provide consumers with all of their retail needs at one location. Many of these retail pharmacies rely substantially on the sale of non-prescription drugs or health and beauty related products to generate revenue.  The business model of retail pharmacies is generally not focused or dedicated to physicians practicing in pain management. These retail pharmacies traditionally keep in inventory non-prescription drugs, or health and beauty related products such as walking canes, bandages and shampoo.  Consumers are able to have their prescriptions filled at these retail pharmacies, but typical retail pharmacies either do not keep in inventory or keep limited amounts of Class II drugs in inventory. As a result, the time it takes for traditional retail pharmacies to fill a prescription for Class II drug is extended. Because of our pain management focus, we maintain an appropriate inventory level of Class II drugs to meet the needs of the patients of physicians that send prescriptions to our pharmacies. We view our ability to fill a prescription for Class II drugs without any period of delay as one our competitive strengths.  We do not intend to sell over-the-counter medication or fill prescriptions unrelated to chronic pain management or other similar recurring conditions at our pharmacies. We will fill prescriptions that address any side effects experienced by individuals who have health conditions that require them to be treated for chronic pain.
 
Research and Development
 
We did not incur any research and development expenditures in either the fiscal year ended December 31, 2012 or the fiscal year ended December 31, 2011.
 
Existing and Probable Governmental Regulation
 
Pharmacy operations are subject to significant governmental regulation on the federal and state level. Compliance with governmental regulation is essential to continued operations. We believe that we are in compliance with each of the laws, rules, and regulations set forth below and have not experienced any incidence of noncompliance.
 
 
 
 

 
 
- 22 -

 
 
 
 
Licensure Laws
 
Each state’s board of pharmacy enforces laws and regulations governing pharmacists and pharmacies. Each of our pharmacies applied and received a license. In addition, each pharmacy must employ a licensed pharmacist to serve as the Pharmacist in Charge (“PIC”). The PIC oversees personnel and reports on the operations at a specific pharmacy. State law regulates the number of employees and clerks that can work under the supervision of one PIC.  Licensure requires strict compliance with state pharmacy standards.
 
Although we believe our pharmacies are compliant, changes in pharmacy laws and differing interpretations regarding such laws could impact our level of compliance. A pharmacy’s failure to comply with applicable law and regulation could result in licensure revocation as well as the imposition of fines and penalties.
 
Drug Enforcement Laws
 
The United States Department of Justice enforces the Drug Enforcement Act through the DEA. The DEA strictly enforces regulations governing controlled substances. In addition to regulation by the DEA, we are subject to significant state regulation regarding controlled substances. Because our pharmacies’ operations focus on highly regulated pain medications, failure to adhere to DEA and state controlled substance requirements could jeopardize our ability to operate. While we believe we are in compliance with current DEA requirements, such requirements and interpretation of these requirements do change over time.
 
Federal Health Programs
 
As we grow, we believe that a significant amount of our revenues will be derived from governmental programs such as Medicaid. With the passage of the Medicare Modernization and Prescription Drug Act of 2003, we also believe that Medicare will become a significant source of funding.
 
The Federal Health Care Programs Anti-Kickback Act
 
Federal law prohibits the solicitation or receipt of remuneration in return for referrals and the offer or payment of remuneration to induce the referral of patients or the purchasing, leasing, ordering or arranging for any good, facility, service or item for which payment may be made under a “federal health care program” (defined as “any plan or program that provides health benefits, whether directly, through insurance, or otherwise, which is funded directly, in whole or in part, by the United States Government other than the Federal Employees Health Benefit Program”).
 
Because our business and operations involve providing health care services, we are subject to the Federal Health Care Programs Anti-Kickback Act (the “Act “). The Anti-Kickback Statute, codified in 42 U.S.C. § 1320a-7b(b), prohibits individuals and entities from knowingly and willfully soliciting, receiving, offering or paying any remuneration to other individuals and entities (directly or indirectly, overtly or covertly, in cash or in kind):
 
  
In return for referring an individual to a person for the furnishing or arranging of any item or service for which payment maybe made under a federal or state healthcare program; or
  
In return for purchasing, leasing, ordering, or arranging for or recommending purchasing, leasing or ordering any good, facility, service or item from which payment may be made under a federal or state health care program.

 There are both criminal and civil penalties for violating the Act. Criminal sanctions include a fine not to exceed $25,000 or imprisonment up to five years or both, for each offense. In addition, monetary penalties for each offense may be increased to up to $250,000 for individuals and up to $500,000 for organizations. Civil penalties include fines of up to $50,000 for each violation, monetary damages up to three times the amount paid for referrals and/or exclusion from the Medicare program. Courts have broadly construed the Anti-Kickback Statute to include virtually anything of value given to an individual or entity if one purpose of the remuneration is to influence the recipient’s reason or judgment relating to referrals.
 
The Department of Health and Human Service’s Office of Inspector General (“OIG”) promulgated safe harbor regulations specifying payment practices that will not be considered to violate the statute. If a payment practice falls within one of the safe harbors, it will be immune from criminal prosecution and civil exclusion under the Act even if it fails to fall within another potentially applicable safe harbor. Significantly, failure to fall within any safe harbor does not necessarily mean that the payment arrangement violates the statute. Failure to comply with a safe harbor can mean one of three things: (1) the arrangement does not fall within the broad scope of the anti-fraud and abuse rules so there is no risk of prosecution; (2) the arrangement is a clear statutory violation and is subject to prosecution; or (3) the arrangement may violate the anti-fraud and abuse rules in a less serious manner, in which case there is no way to predict the degree of risk.
 
 
 
 
 
 
- 23 -

 
 

 
Because our pharmacies maintain relationships with referring physicians, our operations are subject to scrutiny under the Act.
 
If our operations fail to comply with the Act, we could be criminally sanctioned. In addition, the right of any of our pharmacies to participate in governmental health plans could be terminated.  We have a compliance program to ensure that we are in compliance with the Act.
 
Ethics in Patient Referrals Act
 
The Ethics in Patient Referrals Act, 42 U.S.C. §1395nn, commonly referred to as Stark II (“Stark II”), prohibits physicians from referring or ordering certain Medicare or Medicaid reimbursable “designated health services” from any entity with which the physician or any immediate family member of the physician has a financial relationship. A financial relationship is generally defined as a compensation or ownership/investment interest. The purpose of the prohibition is to assure that physicians base their treatment decisions upon the needs of the patients and not upon any financial benefit that would inure to the physician as a result of the referral.
 
Prescription medications are classified as “designated health services” under Stark II. Physicians owning stock in our company are not allowed to refer any Medicare or Medicaid patient to any of our pharmacies until and unless our company’s capitalization exceeds $75,000,000. A referral made in violation of Stark II results in non-payment to the pharmacy and could result in the imposition of fines and penalties as well as termination of our participation in Medicare and Medicaid.

 State Fraud and Abuse Laws
 
Certain of the states in which we operate have adopted their own laws similar to the Act and Stark II. However, in some instances, state laws apply to all health care services, regardless of whether such services are payable by a government health plan. For example, in California, physicians and other practitioners are not permitted to own more than 10% of any entity that owns a pharmacy.
 
HIPAA
 
We are impacted by the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), which mandates, among other things, the adoption of standards to enhance the efficiency and simplify the administration of the healthcare system. HIPAA requires the Department of Health and Human Services to adopt standards for electronic transactions and code sets for basic healthcare transactions such as payment and remittance advice (“transaction standards”); privacy of individually identifiable healthcare information (“privacy standards”); security and electronic signatures (“security standards”), as well as unique identifiers for providers, employers, health plans and individuals; and enforcement. We are required to comply with these standards and are subject to significant civil and criminal penalties for failure to do so.
 
Management believes that we are in material compliance with these standards. However, HIPAA’s privacy and transaction standards only recently became effective, and the security standards are mandatory as of April 21, 2005. Considering HIPAA’s complexity, there can be no assurance that future changes will not occur. Changes in standards as well as changes in the interpretation of those standards could require us to incur significant costs to ensure compliance.
 
Management anticipates that federal and state governments will continue to review and assess alternate healthcare delivery systems, payment methodologies and operational requirements for pharmacies. Given the continuous debate regarding the cost of healthcare services, management cannot predict with any degree of certainty what additional healthcare initiatives, if any, will be implemented or the effect that any future legislation or regulation may have on us.
 
 

 
 
 
- 24 -

 
 
 
OBRA 1990
 
Our business is subject to various other federal and state regulations. For example, pursuant to the Omnibus Budget Reconciliation Act of 1990 (“OBRA”) and comparable state regulations, our pharmacists are required to offer counseling, without additional charge, to our customers about medication, dosage, delivery systems, common side effects and other information deemed significant by the pharmacists and may have a duty to warn customers regarding any potential adverse effects of a prescription drug if the warning could reduce or negate such effect.
 
2010 Health Care Legislation
 
The Patient Protection and Affordable Care Act and the reconciliation law known as Health Care and Education Affordability Reconciliation Act (combined we refer to both Acts as the “2010 Health Care Reform Legislation”) were enacted in March 2010. State participation in the expansion of Medicaid under the 2010 Health Care Reform Legislation is voluntary. Three key provisions of the 2010 Health Care Reform Legislation that are relevant to the Corporation are: (i) the gradual modification to the calculation of the Federal Upper Limit (“FUL”) for drug prices and the definition of Average Manufacturer’s Price (“AMP”), (ii) the closure, over time, of the Medicare Part D coverage gap, which is otherwise known as the “Donut Hole,” and (iii) short cycle dispensing. Regulations under the 2010 Health Care Reform Legislation are expected to continue being drafted, released, and finalized throughout the next several years. Pending the promulgation of these regulations, the Company is unable to fully evaluate the impact of the 2010 Health Care Reform Legislation.
 
FUL and AMP Changes
 
The 2010 Health Care Legislation amended the Deficit Reduction Act of 2005 (the “DRA”) to change the definition of the FUL by requiring the calculation of the FUL as no less than 175% of the weighted average, based on utilization, of the most recently reported monthly AMP for pharmaceutically and therapeutically equivalent multi-source drugs available through retail community pharmacies nationally.
 
In addition, the definition of AMP changed to reflect net sales only to drug wholesalers that distribute to retail community pharmacies and to retail community pharmacies that directly purchase from drug manufacturers. Further, the 2010 Health Care Legislation continues the current statutory exclusion of prompt pay discounts offered to wholesalers and adds three other exclusions to the AMP definition: i) bona fide services fees; ii) reimbursement for unsalable returned goods (recalled, expired, damaged, etc.); and iii) payments from and rebates/discounts to certain entities not conducting business as a wholesaler or retail community pharmacy. In addition to reporting monthly, the manufacturers will be required to report the total number of units used to calculate each monthly AMP. The Center for Medicare & Medicaid (“CMS”) will use this information when it establishes the FUL pursuant to the 2010 Health Care Legislation. Manufacturers made their first reports of AMP to CMS in October 2010. CMS is reviewing the information reported by the manufacturers and has yet to revise the FUL based on its analysis of AMP.
 
On February 2, 2012, CMS issued a proposed regulation further clarifying the AMP and FUL changes described above and indicated that the final rule will be issued sometime in 2013. Until CMS provides additional guidance, we are unable to fully evaluate the impact of the changes in FUL and AMP to our business.
 
Part D Coverage Gap
 
Starting on January 1, 2011, the Medicare Coverage Gap Discount Program (the “Program”) requires drug manufacturers to provide a 50% discount on the negotiated ingredient cost to certain Part D beneficiaries for certain drugs and biologics purchased during the coverage gap (this is exclusive of the pharmacy dispensing fee). In addition, the 2010 Health Care Legislation includes a requirement that closes or eliminates the coverage gap entirely by fiscal year 2020. The coverage gap will be eliminated by gradually reducing the coinsurance percentage for both drugs covered and not covered by the Program for each applicable beneficiary. At this time, we are unable to fully evaluate the impact of the changes to the coverage gap to our business.
 
Reimbursement
 
Medicare is a federal program that provides certain hospital and medical insurance benefits to persons age 65 and over and to certain disabled persons. Medicaid is a medical assistance program administered by each state that provides healthcare benefits to certain indigent patients. Within the Medicare and Medicaid statutory framework, there are substantial areas subject to administrative rulings, interpretations, and discretion that may affect payments made under Medicare and Medicaid.
 
 
 
 
 
 
- 25 -

 

 
We receive payment for our services from commercial Medicare Part D Plans, third party payors government reimbursement programs such as Medicare and Medicaid, and other non-government sources such as commercial insurance companies, health maintenance organizations, preferred provider organizations, and contracted providers.
 
Other Laws
 
 In recent years, an increasing number of legislative proposals have been introduced or proposed in Congress and in some state legislatures that would affect major changes in the healthcare system, either nationally or at the state level. The legislative initiatives include prescription drug benefit proposals for Medicare participants. Although we believe we are well positioned to respond to these developments, we cannot predict the outcome or effect of legislation resulting from these reform efforts.
 
Compliance with Environmental Laws
 
We did not incur any costs in connection with the compliance with any federal, state, or local environmental laws.
 
Employees
 
We currently have 38 full time and 36 part time employees. Our employees are not represented by labor unions or collective bargaining agreements.
 
Properties
 
We are currently leasing our executive offices and pharmacy locations. Our executive offices are located at 5600 Tennyson Parkway, Suite 390, Plano, Texas 75024 and consist of approximately 1,500 square feet.  Monthly rent under the lease for our executive offices is approximately $3,000.
 
Each of our retail pharmacies are approximately 1,500 square feet and are leased from various property management companies for approximately five years.  Monthly rent under each of the lease for our pharmacies ranges from $1,200 to $3,700.
 
Future store locations, when established, will be selected based on the following criteria: i) the proximity to physician and medical facilities; ii) convenience of the particular location; iii) size and growth rate of the surrounding metropolitan area; iv) state and local tax rates; v) competitive business environment and vi) access to qualified personnel and the associated cost.
 
Legal Proceedings
 
From time to time, we may be involved in various claims, lawsuits, and disputes with third parties, actions involving allegations of discrimination or breach of contract actions incidental to the normal operations of the business.  Providing pharmacy services entails an inherent risk of medical and professional malpractice liability. We may be named as a defendant in such lawsuits and thus become subject to the attendant risk of substantial damage awards. We believe that we have adequate professional and medical malpractice liability insurance coverage. There can be no assurance, however, that we will not be sued, that any such lawsuit will not exceed our insurance coverage, or that we will be able to maintain such coverage at acceptable costs and on favorable terms.
 
On March 18, 2011, a lawsuit was filed by Tim Chandler, Jodi Marshall, Christie Garner, the Estate of Thomas Pike, Jr., and Angie Hernandez in the Circuit Court of the State of Oregon for Multnomah County against Payette Clinics, P.C., Scott Pecora, Kelly Bell, Penny Steers and our wholly-owned subsidiaries, Assured Pharmacies Northwest, Inc. and Assured Pharmacy Gresham, Inc. The lawsuit arises from allegations that nurse practitioners at Payette Clinics, P.C. prescribed the five plaintiffs controlled substances in amounts that were excessive under the appropriate medical standard of care.  Only one of the plaintiffs, Tim Chandler, brought claims against our subsidiaries.  Mr. Chandler’s claims against our subsidiaries were for negligence on the basis of allegations that our subsidiaries knew or had reason to know that the prescriptions fell below the standard of care applicable to the prescription of such controlled substances but nonetheless filled the prescriptions.  The plaintiffs, as a whole, submitted a prayer for $7,500,000 in damages.  Mr. Chandler only seeks “an amount to be proven at trial” for noneconomic damages and unnecessary expenses.  Management believes that the allegations against our subsidiaries are without merit and plans to vigorously defend this claim.  We have $2,000,000 in insurance coverage for claims relating to pharmacy negligence.  This lawsuit has been stayed as a result of a co-defendant in this lawsuit (Payette Clinics, P.C.) having filed for bankruptcy.  Although the bankruptcy has been discharged and the automatic stay lifted.  The state court stay has also been lifted and the case is now proceeding.  The Company has denied any liability and is vigorously defending this action.
 
 
 
 
 
 
- 26 -

 
 
 
 
 
Market Information
 
Our common stock is currently quoted on the OTC Markets. The OTC Markets are a network of security dealers who buy and sell stock. The dealers are connected by a computer network that provides information on current “bids” and “asks”, as well as volume information. Our shares are quoted on the OTC Markets under the symbol “APHY.”
 
The following table sets forth the range of high and low closing bid quotations for our common stock for each of the periods indicated as reported by the OTC Markets. These quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not necessarily represent actual transactions.  As of the close of business on April 15, 2011, we effectuated a 1-for-180 reverse stock split.  All prices in the following table reflect post-reverse split prices.
 
Fiscal Quarter Ended March 31, 2013
 
 
High Bid
Low Bid
Fiscal Quarter Ended:
   
March 31, 2013
$0.92
$0.35
     
Fiscal Year Ended December 31, 2012
 
 
High Bid
Low Bid
Fiscal Quarter Ended:
   
March 31, 2012
$0.80
$0.20
June 30, 2012
$0.90
$0.34
September 30, 2012
$0.61
$0.50
December 31, 2012
$0.50
$0.20
     
Fiscal Year Ended December 31, 2011
 
 
High Bid
Low Bid
Fiscal Quarter Ended:
   
March 31, 2011
$1.35
$0.43
June 30, 2011
$1.16
$0.01
September 30, 2011
$1.15
$0.65
December 31, 2011
$0.75
$0.51
 
On June 4, 2013, the last practicable date before the date of this prospectus, the closing price for our common stock on the OTC Markets was $0.89 per share.
 
Holders of Common Stock
 
As of May 31, 2013, there were approximately 152 record holders of our common stock.  This number does not include stockholders whose shares are held in securities position listings.
 
 
 

 
 
- 27 -

 
 
 
 
Securities Authorized for Issuance Under Equity Compensation Plans
 
The following table, which has been adjusted to reflect a 1-for-180 reverse stock split that was effective on April 15, 2011, provides information about our compensation plans under which shares of common stock may be issued upon the exercise of options and warrants as of December 31, 2012:
 
Plan category
 
Number of securities
to be issued upon
exercise of outstanding options, warrants
 and rights
(a)
 
Weighted-average
exercise price of
outstanding options,
warrants and rights
(b)
 
Number of securities
remaining available for
future issuance under
equity compensation plans
(excluding securities
reflected in column (a))
(c)
             
Equity compensation plans
    approved by stockholders
  525,000   $0.60   1,142,667
Equity compensation plans
   not approved stockholders
 
1,315,556
 
$0.69
 
-
Total
 
1,840,556
 
$0.66
 
1,142,667
 
 
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
 
The following discussion should be read in conjunction with our Financial Statements and notes thereto appearing elsewhere in this prospectus. This discussion contains forward-looking statements and involves numerous risks and uncertainties, including, but not limited to, those described in the “Risk Factors” section of this prospectus. Actual results may differ materially from those contained in any forward-looking statements. See also “Cautionary Notice Regarding Forward-Looking Statements” found elsewhere in this prospectus.
 
Overview
 
We are engaged in the business of establishing and operating pharmacies that specialize in dispensing highly regulated pain medication for chronic pain management.  Because our focus is on dispensing medication, we typically do not keep in inventory non-prescription drugs, or health and beauty related products, such as walking canes, bandages and shampoo. We primarily derive our revenue from the sale of prescription medications.   The majority of our business is derived from repeat business from our customers.
 
We currently have four operating pharmacies, each of which are wholly owned through subsidiaries. The opening date and locations of our pharmacies are as follows:
 
Location
 
Opening Date
 
Riverside, California
 
June 10, 2004
Kirkland, Washington
 
August 11, 2004
Gresham, Oregon
 
January 26, 2007
Leawood, Kansas
 
November 28, 2011

 
 
 
 

 
 
- 28 -

 
 
 
 
Results of Operations for the Three Months Ended March 31, 2013 and March 31, 2012
 
The table set forth below summarizes the number of prescriptions dispensed by our operating pharmacies during the periods indicated.
 
   
Three months ended
   
Three months ended
 
   
March 31, 2013
   
March 31, 2012
 
             
Total Number of Prescriptions 1
    25,700       29,952  
                 
Total Number of Patients Serviced 2
    11,484       10,835  
 
 
1
“Total Number of Prescriptions” equals the total number of prescriptions dispensed by our operating pharmacies and delivered to or picked up by the customer.
 
 
2
“Total Number of Patients Serviced” equals the total number of patients serviced measured on a monthly basis.
 
The following table sets forth for the periods indicated certain items from our Consolidated Statement of Operations as a percentage of current sales:
 
   
Three Months Ended March 31,
 
   
2013
   
2012
 
             
Sales
   
100.0
%
   
100.0
%
Cost of sales
   
76.8
     
79.7
 
Gross profit
   
23.2
     
20.3
 
Operating expenses
               
Salaries and related expenses
   
25.1
     
19.8
 
Selling, general and administrative
   
21.4
     
15.9
 
   Total operating expenses
   
46.5
     
35.7
 
Loss from operations
   
-23.3
     
-15.4
 
Other expenses
               
Interest expense, net
   
10.0
     
10.3
 
Loss on change in fair value of forward contract
   
2.2
     
-
 
(Gain) or loss on change in fair value of warrant liability
   
3.8
     
-1.1
 
    Total other expenses and income
   
15.9
     
9.2
 
Net loss
   
-39.2
     
-24.6
 
 
Sales
 
Our total sales reported for the three months ended March 31, 2013 was $2,893,295, a 20.7% decrease from $3,647,410 for the three months ended March 31, 2012. Our sales for the three months ended March 31, 2013 and 2012 was generated primarily from the sale of prescription drugs through our pharmacy operations and to a much lesser extent fees from management services provided.
 
Our total sales from pharmacy operations for the three months ended March 31, 2013 was $2,877,906, a 20.7 % decrease from $3,628,953 for the three months ended March 31, 2012. Sales per prescription dispensed for pharmacies that were open a least one year was approximately $112 per prescription for the three months ended March 31, 2013, an 7.5% decrease from approximately $121 per prescription for the three months ended March 31, 2012.  The decrease in sales per prescription dispensed is primarily attributable to a shift in prescription mix from higher priced brand medications to lower priced generic medications.  
 
The number of prescriptions dispensed by our pharmacies was 25,700 for the three months ended March 31, 2013 compared to 29,952 for the three months ended March 31, 2012.  Management attributes the decrease in prescription volumes to inventory purchasing constraints due to working capital limitations.
 
Our total sales from management services for the three months ended March 31, 2013 was $15,389, a decrease from $18,457 in sales for the three months ended March 31, 2012.
 
 
 
 
 
 
 
- 29 -

 
 
 
 
Cost of Sales
 
The total cost of sales for the three months ended March 31, 2013 was $2,221,035, a 23.6% decrease from $2,908,421 for the three months ended March 31, 2012. The cost of sales consists primarily of the direct cost of prescription drugs. The decrease in cost of sales is primarily attributable to decreased sales in the reporting period.
 
Gross Profit
 
Our total gross profit decreased to $672,260 or approximately 23.2% of sales, for the three months ended March 31, 2013. This is a decrease from a gross profit of $738,989, or approximately 20.3% of sales for the three months ended March 31, 2012.  Our gross profit from pharmacy revenues decreased to $656,871 or approximately 22.8% of pharmacy revenues, for the three months ended March 31, 2013.  This is an increase from a gross profit of $720,532 or approximately 19.9% of pharmacy revenues, for the three months ended March 31, 2012.
 
The increase in the gross profit percentage for the three months ended March 31, 2013 when compared to the prior fiscal three months is primarily attributable to an increase in sales of generic drugs as a percentage of total prescription revenue which have lower costs and higher gross profit margins.  Additionally, our drug pricing improved from our restructuring purchasing account with our primary wholesaler in February 2013. The restructuring allows us to take advantage of additional discounts available.
 
Operating Expenses
 
Operating expenses for the three months ended March 31, 2013 was 1,346,049, a 3.5% increase from $1,301,099 for the three months ended March 31, 2012. Our operating expenses for the three months ended March 31, 2013 consisted of salaries and related expenses of $726,689 and selling, general and administrative expenses of $619,360.  Our operating expenses for the three months ended March 31, 2012 consisted of salaries and related expenses of $722,050 and selling, general and administrative expenses of $579,049.
 Selling, general and administrative expenses increased $40,311 in the three months ended March 31, 2013 when compared to the previous fiscal three months.  The significant components of selling, general and administrative expenses are as follows:
 
   
Three months ended March 31,
 
   
2013
   
2012
 
             
Stock-based compensation expenses
   
203,780
     
88,511
 
Recoveries  for other receivables doubtful accounts
   
(30,479
   
-
 
Provision (Recoveries) for accounts receivable doubtful accounts
   
(2,721
   
5,822
 
Selling expenses
   
20,637
     
24,801
 
Professional fees
   
104,119
     
67,874
 
Delivery expenses
   
92,245
     
79,696
 
Facility related expenses
   
84,854
     
73,916
 
Travel and related expenses
   
31,071
     
52,536
 
Vendor late fee expenses
   
6,392
     
50,267
 
Investor relations expense
   
-
     
10,089
 
Other general and administrative expenses
   
109,462
     
125,537
 
Total
 
$
619,360
   
$
579,049
 
 
The increase in selling, general and administrative expenses is primarily due to an increase in stock based compensation, delivery expenses and professional fees which was partially offset by a decrease in bad debt expense, investor relations expense, vendor late fees, travel, and other general and administrative expenses. The increase in stock-based compensation expense and professional fees are primarily related to securing additional financing and expenses associated with being a public company. The increase in delivery expenses are primarily due to an increase in the number of patients serviced by our operating pharmacies, our pharmacies provided services to a total of 11,484 patients in the three months ending March 31, 2013, a 6.0% increase when compared to the 10,835 patients serviced in the previous fiscal three months.  The decrease in vendor late fees is primarily due to the February 2013 account restructuring with our primary wholesaler.
 
 
 
 
 
 
 
- 30 -

 
 
 
 
Other Income and Expense
 
Total other expenses and income for the three months ended March 31, 2013 was $397,010, a $62,093 increase from $334,917 for the three months ended March 31, 2012.  The significant components of other income and expenses are as follows:
 
   
Three months ended March 31,
 
   
2013
   
2012
 
             
Interest expense, net
   
288,046
     
376,011
 
Loss on change in fair value of forward contracts
   
62,214
     
-
 
(Gain) or Loss on change in fair value of warrants
   
108,964
     
(41,094)
 
Total
 
$
459,224
   
$
334,917
 
 
The increase in other expenses was primarily attributable to an increase of $150,058 in the change in fair value of warrant liability and to a lesser extent an increase of $87,965 in interest expense and an increase of $62,214 in change in fair value of forward contracts in the three months ended March 31, 2013 when compared to the previous fiscal three months.
 
 The decrease in interest expense is primarily due to a decrease in amortization of debt discount which was partially offset by an increase in interest expense at the stated rate due to an increase in the average debt outstanding for the three months ended March 31, 2013 as compared to the three months ended March 31, 2012.   The table below summarizes the components of interest expense for the three months ended March 31, 2013 and 2012:
 
   
Three months ended March 31,
 
   
2013
   
2012
 
             
Interest expense at stated rates (6.25% - 20.00%)
 
$
190,888
   
$
141,650
 
Amortization of deferred financing costs
   
9,767
     
41,855
 
Amortization of debt discount
   
87,391
     
192,506
 
Interest expense, net
 
$
288,046
   
$
376,011
 
 
The gain or loss on change in fair value of warrant liability represents the change in fair value calculated on warrants issued in connection with private placements from May 2011 through March 31, 2013 which grant the warrant holder certain anti-dilution protection which provide exercise price adjustments in the event that any common stock or common stock equivalents are issued at an effective price per share that is less than the exercise price per share.
 
The loss on change in fair value of forward contracts represents the change in fair value calculated on the Make Whole Provision issued in connection with private placements in February 2013 which grant the shareholder certain protection in the event that 2013 revenues due not  achieve agreed upon revenue milestones.
 
Net Loss
 
Our net loss for the three months ended March 31, 2013 was $1,133,013, compared to a net loss of $897,027 for the three months ended March 31, 2012. The increase in our net loss was primarily attributable to decreasing sales, an increase in other expenses and income, a decrease in gross profits and to a lessor extent an increase in operating expenses.
 
Basic and Diluted Income (Loss) per Share
 
Our net loss per common share for the three months ended March 31, 2013 was $0.23, compared to a net loss per common share of $0.23 for the three months ended March 31, 2012.  The decrease to our net loss per common share was primarily attributable to an increase in the weighted average number of common shares outstanding to 4,901,040 for the three months ended March 31, 2013, from 3,829,017 for the three months ended March 31, 2012 and a $235,986 increase in our net loss for the three months ended March 31, 2013 when compared to the three months ended March 31, 2012.

 
 
 
 
- 31 -

 
 
 
 
Results of Operations for the Years Ended December 31, 2012 and 2011
 
The table set forth below summarizes the number of prescriptions dispensed by our operating pharmacies during the periods indicated.
 
   
Year ended
   
Year ended
 
   
December 31, 2012
   
December 31, 2011
 
             
Total Number of Prescriptions 1
    121,392       117,410  
                 
Total Number of Patients Serviced 2
    48,177       39,695  
 
1   “Total Number of Prescriptions” equals the total number of prescriptions dispensed by our operating pharmacies and delivered to or picked up by the customer.
2   “Total Number of Patients Serviced” equals the total number of patients serviced measured on a monthly basis.
 
Summarized immediately below and discussed in more detail in the subsequent sub-sections is an analysis of our operating results for the years ended December 31, 2012 and 2011, represented as a percentage of total sales for each respective period:
 
 
   
Year Ended December 31,
 
   
2012
   
2011
 
             
Sales
   
100.0
%
   
100.0
%
Cost of sales
   
78.3
     
80.4
 
Gross profit
   
21.7
     
19.6
 
Operating expenses
               
Salaries and related expenses
   
21.7
     
17.3
 
Selling, general and administrative
   
19.8
     
19.1
 
   Total operating expenses
   
41.5
     
36.4
 
Loss from operations before non-controlling interest
   
-19.8
     
-16.8
 
Other expenses
               
Interest expense, net
   
10.4
     
5.6
 
Loss on extinguishment of debt
   
0.6
     
0.1
 
Gain on change in fair value of warrant liability
   
-2.5
     
-2.7
 
    Total other expenses and income
   
8.5
     
3.0
 
Net loss from operations before non-controlling interest
   
-28.3
     
-19.8
 
Net income attributable to non-controlling interest
   
-
     
-0.1
 
Net loss attributable to Assured Pharmacy, Inc.
   
-28.3
     
-19.9
 

 
 
 
 
 
 
 
- 32 -

 
 
 
 
Sales
 
Our total sales reported for the year ended December 31, 2012 was $14,145,533, a 14.0% decrease from $16,444,573 for the year ended December 31, 2011. Our sales for the year ended December 31, 2012 and 2011 was generated primarily from the sale of prescription drugs through our pharmacy operations and to a much lesser extent fees from management services provided. Our total sales from pharmacy operations for the year ended December 31, 2012 was $14,073,961, a 13.9% decrease from $16,354,578 for the year ended December 31, 2011.  Our total sales from management services for the year ended December 31, 2012 was $71,572, a 20.5% decrease from $89,995 for the year ended December 31, 2011.
 
Sales per prescription dispensed by our pharmacies was approximately $116 per prescription for the year ended December 31, 2012, a 16.8% decrease from approximately $139 per prescription for the year ended December 31, 2011.  The decrease in sales per prescription dispensed is primarily attributable to a shift in prescription mix from higher priced brand medications to lower priced generic medications. Management attributes this shift in prescription mix to changes in physician and patient mix, additional generic medications being available on the market, changes in insurance coverage, reformulation of existing pain medications and inventory constraints due to working capital limitations.  Management attributes the increase in prescription volumes primarily to our direct sales efforts, which was partially offset by inventory purchasing constraints due to working capital limitations.
 
Cost of Sales
 
The total cost of sales for the year ended December 31, 2012 was $11,078,407, a 16.2% decrease from $13,220,684 for the year ended December 31, 2011. The cost of sales consists primarily of direct cost of prescription drugs. The decrease in cost of sales is primarily attributable to decreased sales in the reporting period.
 
Gross Profit
 
Our total gross profit decreased to $3,067,126, or approximately 21.7% of sales, for the year ended December 31, 2012. This is a decrease from a gross profit of $3,223,889, or approximately 19.6% of sales for the year ended December 31, 2011.  Our gross profit from pharmacy sales decreased to $2,995,554, or approximately 21.2% of pharmacy revenues, for the year ended December 31, 2012.  This is a decrease from a gross profit of $3,133,894, or approximately 19.2% of pharmacy sales, for the year ended December 31, 2011.
 
The increase in the gross profit percentage for the year ended December 31, 2012, when compared to the prior fiscal year, is primarily attributable to an increase in sales of generic drugs as a percentage of total prescription sales which has lower costs and higher gross margins.
 
Operating Expenses
 
Operating expense for the year ended December 31, 2012 was $5,864,263, a 2.1% decrease from $5,990,868 for the year ended December 31, 2011. Our operating expenses for the year ended December 31, 2012 consisted of salaries and related expenses of $3,065,982 and selling, general and administrative expenses of $2,798,281. Our operating expenses for the year ended December 31, 2011 consisted of salaries and related expenses of $2,850,034 and selling, general and administrative expenses of $3,140,834.
 
Salaries and related expenses increased in the year ended December 31, 2012, when compared to the previous fiscal year, primarily due to the addition of our Kansas City pharmacy in November 2011 which was partially offset by staff reductions at our existing pharmacies and at the corporate level.
 
 
 
 
 
 
 
- 33 -

 
 
 
 
Selling, general and administrative expenses decreased $342,553 in the year ended December 31, 2012 when compared to the previous fiscal year.  The significant components of selling, general and administrative expenses are as follows:
 
   
Year Ended December 31,
 
   
2012
   
2011
 
             
Stock-based compensation expenses
   
851,561
     
782,643
 
Provision for other receivables doubtful accounts
   
(136,038
)
   
659,616
 
Provision for accounts receivable doubtful accounts
   
30,610
     
65,322
 
Selling expenses
   
105,787
     
88,771
 
Professional fees
   
484,351
     
196,330
 
Delivery expenses
   
365,653
     
298,720
 
Facility related expenses
   
311,114
     
249,363
 
Travel and related expenses
   
165,156
     
150,858
 
Vendor late fee expenses
   
105,508
     
108,726
 
Investor relations expense
   
10,089
     
61,273
 
Other general and administrative expenses
   
504,490
     
 479,212
 
Total
 
$
2,798,281
   
$
3,140,834
 
 
The decrease in selling, general and administrative expenses is primarily due to a decrease in provision for other receivables doubtful accounts of $795,654 and to a lesser decreases in investor relations expense, provision for accounts receivable doubtful accounts, vendor late fee expenses and other general and administrative expenses which were partially offset by increases in professional fees, stock based compensation, delivery expenses, facility related expenses, selling expenses and travel expenses. The decrease in bad debt expense primarily relates to increased collection activity on our past due other receivable accounts. The increase in stock-based compensation expense and professional fees are primarily related to securing additional financing and expenses associated with filing our registration statement. The increase in delivery expenses are primarily due to an increase in the number of patients serviced by our operating pharmacies, our pharmacies provided services to a total of 48,177 patients for the year ending December 31, 2012, a 20.5% increase when compared to the 39,965 patients serviced in the previous fiscal year. The increases in facility related expenses, travel expenses and selling expenses primarily relate to our Kansas City pharmacy which opened in November 2011.
 
Other Income and Expense
 
Total other expenses and income for the year ended December 31, 2012 was $1,208,369, a $716,387 increase from $491,982 for the year ended December 31, 2011.  The significant components of other income and expenses are as follows:
 
   
Year ended December 31,
 
   
2012
   
2011
 
             
Interest expense, net
   
1,475,358
     
918,333
 
Loss on extinguishment of debt
   
90,205
     
16,923
 
Gain on change in fair value of warrants
   
(357,194
)
   
(443,274
)
Total
 
$
1,208,369
   
$
491,982
 
 
The increase was primarily attributable to an increase in interest expense of $557,025 and to a lesser extent an increase of $73,282 in loss on extinguishment of debt and a decrease of $86,080 in the change in fair value of warrant liability.
 
The increase in interest expense is primarily due to an increase in the average debt outstanding the year ended December 31, 2012 compared to the year ended December 31, 2011.  We issued convertible debentures in January and July 2012, throughout the fiscal year 2011 and in December 2010 and increased our borrowing under revolving credit facilities to fund our operations and open our new pharmacy in Leawood, Kansas.

 
 
 
 
 
- 34 -

 
 
 
 
 
Our total outstanding debt increased to $3,960,293 as of December 31, 2012 as compared to $3,367,314 at December 31, 2011. Interest expense also increased due to the full year amortization of debt discounts on existing debt as well as the additional amortization related to new indebtedness.  The table below summarizes the components of interest expense for the year ended December 31, 2012 and 2011:
 
   
Year Ended December 31,
 
   
2012
   
2011
 
                 
Interest expense at stated rates (6.25% - 20.00%)
 
$
668,768
   
$
374,848
 
Amortization of deferred financing costs
   
121,963
     
71,416
 
Amortization of debt discount
   
684,627
     
472,069
 
Interest expense, net
 
$
1,475,358
   
$
918,333
 
 
The $90,205 loss on extinguishment of debt for the year ended December 31, 2012 resulted from the modification and extension of seven convertible debenture agreements that met the requirements for extinguishment accounting treatment.  The loss on extinguishment of debt of $16,923 in the year ended December 31, 2011 relates to the cancellation of $300,000 in convertible debentures and related warrants in exchange for a 16% convertible debenture due December 1, 2012.
 
The gain on change in fair value of warrant liability represents the change in fair value calculated on warrants issued in connection with private placements in the fiscal years 2011and 2012 which grant the warrant holder certain anti-dilution protection and provide exercise price adjustments in the event that any common stock or common stock equivalents are issued at an effective price per share that is less than the exercise price per share.
 
Net income attributable to non-controlling interest
 
Net income attributable to non-controlling interest for the year ended December 31, 2012 was $0 compared to income of $12,051 for the year ended December 31, 2011. Income and losses are allocated to non-controlling interest holders based on their percentage during the year.  On June 30, 2011, we entered into a Stock Purchase Agreement with TAPG and issued 300,000 restricted shares of our common stock in exchange for all of TAPG’s rights, title and interest in APN and the cancellation of the $17,758 in principal and interest due to TAPG.  As a result of this acquisition, APN became a wholly-owned subsidiary.
 
Net Loss
 
Our net loss for the year ended December 31, 2012 was $4,005,506, compared to a net loss of $3,271,012 for the year ended December 31, 2011. The increase in our net loss was primarily attributable to an increase in other expenses of $716,387 and to a lesser extent, a decrease in gross profit of $156,763 which was partially offset by a decrease in operating expenses of $126,605.
 
Our net loss per common share for the year ended December 31, 2012 was $0.96, compared to a net loss per common share of $1.14 for the year ended December 31, 2011.  The decrease to our net loss per common share was primarily attributable to an increase in the weighted average number of common shares outstanding to 4,150,976 for the year ended December 31, 2012, from 2,876,335 for the year ended December 31, 2011 and a $734,494 increase in our net loss applicable to common stock.

Financial Condition, Liquidity and Capital Resources
 
Liquidity and Capital Resources
 
As of March 31, 2013, we had a cash balance of $11,785, a decrease from a balance of $9,513 at December 31, 2012.  At March 31, 2013, we had a working capital deficit of $6,892,280, an increase of $580,159 from a working capital deficit of $6,312,121 as of December 31, 2012.  The increase in our working capital deficit was primarily due to an increase in current liabilities primarily attributable to an increase in an increase in the current portion of debt.
 
Our operations have been funded primarily through the sale of both equity and debt securities and cash made available under certain credit facilities.  In order for us to finance operations, continue our growth plan and service our existing debt, additional funding will be required from external sources. We intend to fund operations through increased sales, increased collection activity on other receivables and debt and/or equity financing arrangements, which may be insufficient to fund our capital expenditures, working capital, or other cash requirements for the next twelve months.  However, there can be no assurance that the additional financing necessary to finance our operations for the next twelve months will be available to us on acceptable terms, or at all.

 
 
 
 
 
 
- 35 -

 
 
 

 
As of March 31, 2013, $540,310 of our debt obligations due in 2012 are past due and another $2,263,312 is coming due by December 31, 2013.  If our debt holders choose not to convert certain of these securities into equity or seek to enforce these obligations against us, we will need to repay such debt, or reach an agreement with the debt holders to extend the terms thereof.  If we are forced to repay the debt, this need for funds would have a material adverse impact on our business operations, financial condition and prospects, including our ability to operate as a going concern.  If we are forced to repay the debt, our current and forecasted levels of cash flows and available cash on hand will not be sufficient to fund our operations for the remainder of 2013. Accordingly, we will be required to obtain additional financing in order to repay the debt, cover operating losses and working capital needs.  We cannot provide any assurances of the availability of future financing or the terms on which it might be available. In the absence of such financing, we may be forced to scale back or cease operations, liquidate assets, seek additional capital on less favorable terms and/or pursue other remedial measures.   In the event that we are not successful in securing any additional financing or extending the maturity date of those debt securities which come due in 2013, we expect that our current resources will not enable us to continue operations for the remainder of fiscal 2013.
 
The table below lists our obligations under outstanding notes payable and unsecured convertible debentures, as of March 31, 2013: 
 
   
Related
Party
   
Unrelated
   
Total
 
                   
Secured Debt  (1)
   
-
     
3,821,896
     
3,821,896
 
Revolving Credit facilities  (2)
   
453,000
     
-
     
453,000
 
Other Notes and Debt  (3)
   
-
     
242,872
     
242,872
 
Unsecured Convertible Debentures, net of unamortized discount (4)
   
542,169
     
2,134,998
     
2,677,168
 
     
995,169
     
6,199,767
     
7,194,936
 
Less: current portion
   
(520,753
)
   
(5,936,138
)
   
(6,456,891
)
   
$
474,416
   
$
263,629
   
$
738,045
 
 
(1)  
In February 2013, we received a one year loan of $3,828,527 with an interest rate $6.25% per annum, with interest payable monthly. Monthly payment requirements are $27,000 per month for the first four consecutive months, followed by four consecutive monthly payments of $37,000, followed by four consecutive monthly payments of $42,000, with remaining principal and interest due February 1, 2013.
 
(2)  
As of March 31, 2013, revolving credit facilities consisted of an outstanding balance of $453,000 on a line of credit we entered into with Brockington Securities, Inc., a company under the control of our Chief Executive Officer.
 
(3)  
 As of March 31, 2013, other notes and debt consisted of the outstanding principal balance of $242,872 due to TPG in connection with our acquisition of their ownership interest in API. Due to our current financial condition, we did not make the monthly installment payments of $10,000 due September 15, 2012 through March 15, 2013 and may be unable to make the $213,091 payment due to TPG which includes principal and interest on or before July 15, 2013. If we remain unable to fulfill our obligations to TPG under the Purchase Agreement, we will attempt to restructure and extend the terms of payments due to TPG, but can provide no assurance we will be able to do so on acceptable terms or even at all.  In order to secure our obligations under the Purchase Agreement, TPG holds a security interest in the shares of API capital stock acquired by us under the Purchase Agreement. As a result of this transaction, API also became our wholly owned subsidiary. If we are unable to meet our outstanding obligations to TPG under the Purchase Agreement, TPG could declare the us in default and may seize the shares of API capital stock acquired by us under the Purchase Agreement, which would result in API no longer being a wholly owned subsidiary and have a material adverse effect on our business, operating results and financial condition. TPG has not issued a notice of default relating to our failure to make the monthly installment payments of $10,000 due September 15, 2012 through March 15, 2013 required under the Purchase Agreement.
 
(4)  
Our unamortized debt discount of $288,616 at March 31, 2013.

 
 
 
 
 
- 36 -

 

 
 

Outstanding Trade Balance.  At March 31, 2013, we did not have an outstanding trade balance with our primary wholesaler due to conversion of the vendor payable into a secured note in February 2013.
 
Capital Expenditures.  At March 31, 2013, we had no material commitments for capital expenditures.
 
Cash Flows.  As of March 31, 2013, we had $11,785 in cash and total current assets in the amount of $1,346,206 and had current liabilities in the amount of $8,238,486 resulting in a working capital deficit of $6,892,280.
 
The table below sets forth a summary of the significant sources and uses of cash for the three months ended March 31:
 
   
2012
   
2011
 
             
Cash used in operating activities
 
$
(589,644
)
 
$
(62,509
)
Cash used in investing activities
   
(37,334
)
   
(10,676
)
Cash provided by financing activities
   
617,465
     
56,382
 
                 
Decrease in cash
 
$
(9,513
)
 
$
(16,803
)
 
Operating activities used $589,644 in cash for the three months ended March 31, 2013. Our net loss of $1,133,013, less non-cash expenses of $492,198 was the primary reason for our negative operating cash flows.
 
The table below summarizes the components of our cash used in operating activities for the three months ended March 31, 2013:
 
Net loss from operations including non-controlling interest
 
$
(1,133,013
)
         
Adjustments to reconcile net loss to net cash used in operating activities:
       
Depreciation and amortization of property and equipment
   
7,815
 
Amortization of debt issuance costs
   
9,767
 
Amortization of discount on debt
   
87,391
 
Stock based compensation
   
203,780
 
Provision for accounts receivable doubtful accounts
   
(2,721)
 
Provision for other receivable doubtful accounts
   
(30,479
    Issuance of common stock in lieu of debenture interest
   
45,467
 
Loss on change in fair value of forward contract
   
62,214
 
Loss on change in fair value of warrant liability
   
108,964
 
   
$
492,198
 
         
Changes in operating assets and liabilities:
   
51,171
 
         
Net cash used in operating activities
 
$
(589,644
)
 
Cash used in investing activities was $37,334 in the three months ended March 31, 2013, compared to $10,676 in the three months ended March 31, 2012.  Investing activities in the three months ended March 31, 2013 and 2012 consisted entirely of purchases of property and equipment.
 
Cash provided by financing activities during the three months ended March 31, 2013 was $617,465. Over the last several years, our operations have been funded primarily through the sale of debt securities and advances from revolving credit facilities made available to us.  During the three months ended March 31, 2013 we received net proceeds from the issuances of common stock of $569,000, net proceeds of $60,000 from the issuance of Series A preferred stock and net proceeds of $6,000 from shareholder revolving note, which was partially offset by principal repayments of $17,535 on notes payable.
 
Off-Balance Sheet Arrangements
 
As of March 31, 2013, we do not have any off-balance sheet debt nor did we have any transactions, arrangements, obligations (including contingent obligations) or other relationships with any unconsolidated entities or other persons that may have material current or future effect on financial conditions, changes in the financial conditions, results of operations, liquidity, capital expenditures, capital resources, or significant components of revenue or expenses.
 
 
 

 
 
- 37 -

 
 
 
 
 
 
 
Going Concern
 
The consolidated financial statements have been prepared assuming we will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the ordinary course of business. As of March 31, 2013, we had an accumulated deficit of approximately $44.1 million, recurring losses from operations and negative cash flow from operating activities for the nine months ended March 31, 2013 of approximately $589,644. We also had negative working capital of approximately $6.9 million and debt with maturities within the year 2013 in the amount of approximately $2.8 million as of March 31, 2013.
 
We intend to fund operations through raising additional capital through debt financing and equity issuances, increased sales, improved collection of past due other receivables accounts which may be insufficient to fund our capital expenditures, working capital or other cash requirements for the year ending December 31, 2013. We are also in negotiations with current debt holders to restructure and extend payment terms of the existing short term debt.  We are actively seeking additional funds to finance its immediate and long-term operations. The successful outcome of future financing activities cannot be determined at this time and there is no assurance that if achieved, we will have sufficient funds to execute our intended business plan or generate positive operating results. These factors, among others, raise substantial doubt about our ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments related to recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result should we be unable to continue as a going concern.
 
In response to these financial issues, management has taken the following actions:
 
·    
We are seeking to renegotiate existing debt.
·    
We are seeking investment capital.
·    
We are aggressively increasing collection activity on past due other receivable balances.
 
Critical Accounting Policies and Estimates
 
Our analysis and discussion of our financial condition and results of operations is based upon our Consolidated Financial Statements that have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. GAAP provides the framework from which to make these estimates, assumptions and disclosures. We have chosen accounting policies within GAAP that we believe are appropriate to accurately and fairly report our operating results and financial position in a consistent manner. We regularly assess these policies in light of current and forecasted economic conditions. Our accounting policies are stated in Note 2 to the Consolidated Financial Statements included elsewhere in this prospectus.  We believe the following accounting policies are critical to understanding our results of operations and the more significant judgments and estimates used in the preparation of our Consolidated Financial Statements.
 
Revenue Recognition
 
We recognize revenue from prescriptions dispensed on an accrual basis when the product is delivered to or picked up by the customer. Payments are received directly from the customer at the point of sale, or the customers' insurance provider is billed electronically. For third party medical insurance and other claims, authorization to ensure payment is obtained from the customer’s insurance provider before the medication is dispensed to the customer. Authorization is obtained for these sales electronically and a corresponding authorization number is issued by the customers' insurance provider.
 
We recognize revenue from service contracts on an accrual basis when the service is provided to the customer.  In March 2010, we entered into a one year Pharmacy Agreement with Generex to provide pharmacy and marketing services for Generex’s proprietary buccal insulin spray product Oral-lyn™. The Oral-lyn™ product will be dispensed as part of the United States Food and Drug Administration’s Treatment Investigation New Drug Program.  The remuneration for the one year service contract was $300,000, payable on execution of the Pharmacy Agreement.  The Company recognized revenue related to this contract on a straight in basis over the one year term of the contract.
 
 
 
 
 
 
 
- 38 -

 

 
 
 
Accounts Receivable and Allowances
 
Our accounts receivable consist of amounts due from third party medical insurance carriers, pharmacy benefit management companies, patients and credit card processors. Management periodically reviews the accounts receivable to assess collectability and estimate and potential doubtful accounts.  Accounts receivable are written off after collection efforts have been completed in accordance with our policies.  The doubtful accounts allowance reduces the carrying value of the account receivable.
  
Other Receivables and Allowances
 
The other receivables are primarily related to worker’s compensation claims from insurance carriers for prescription medications dispensed to injured workers in the State of California.  The delay in payment typically arises due to monetary disputes between the claimant and the employer and/or the employer’s insurance carrier. The settlement period for such dispute cases can range from one year to ten years.  We typically file a lien (“Green Lien”) on each case that has a past due balance to protect the account receivable when the case ultimately settles. Management has classified such receivables as long term assets due to these factors.  On April 1, 2010, we discontinued dispensing medication to California worker’s compensation customers whose claims could not be authorized and billed electronically.
 
During the year ended December 31, 2011, management performed a comprehensive assessment of the allowance for doubtful accounts for other receivables estimation methodologies in light of its expectations around the ultimate collection of its other receivables balances.  Management performed a detailed case analysis, taking into consideration recent collection history, status of each case and the overall decrease in case activity over the last two years.  In connection with that comprehensive assessment of the allowance for doubtful accounts, management recorded a $659,616 bad debt provision to reduce the other receivables balance to the expected net realizable value. As of December 31, 2012 management assessed its remaining other receivables accounts and updated its overall allowance considering the $136,038 in recovery of accounts previously included in the allowance.
 
Inventories
 
Inventories are located at our pharmacy locations. Inventory consists solely of finished products (primarily prescription drugs) and is valued at the lower of first-in, first-out cost (FIFO) or market. Our inventories are maintained on a periodic basis through the performance of physical inventory counts.  Our cost of sales is recorded based upon the actual results of the physical inventory counts, and is estimated when a physical inventory is not performed in a particular month. Historically, no significant adjustments have resulted from reconciliations with the physical inventories.
 
Inventories are comprised of brand and generic pharmaceutical drugs. Our pharmacies maintain a wide variety of different drug classes, known as Schedule II, Schedule III, and Schedule IV drugs, which vary in degrees of addictiveness.  Schedule II drugs, considered narcotics by the DEA, are the most addictive; hence, they are highly regulated by the DEA and are required to be segregated and secured in a separate cabinet. Schedule III and Schedule IV drugs are less addictive and are not regulated. Because our business model focuses on servicing pain management doctors and chronic pain patients, we carry in inventory a larger amount of Schedule II drugs than most other pharmacies.
 
Stock-based Compensation
 
We issue options and restricted shares of common stock to employees and consultants.  Stock option and restricted share awards are granted at the fair market value of our common stock on the date of grant.
 
We apply the fair value recognition provisions of ASC 718 “Compensation – Stock Compensation,” for stock compensation transactions.  This requires companies to measure and recognize compensation expense for all share-based payments at fair value. The total applicable compensation cost is amortized on a straight-line basis over the requisite service period, which is generally the vesting period.
 
 
 
 
 
 
 
- 39 -

 
 
 
 

Goodwill

Goodwill represents the excess purchase price of an acquired entity over the net amounts assigned to assets acquired and liabilities assumed.  The Company’s goodwill relates to its acquisition of the 49% interest in API.  The Company reviews goodwill for impairment at least annually.  The annual impairment test for goodwill is a two-step process and involves comparing the estimated fair value of each reporting unit to the reporting unit’s carrying value, including goodwill.  If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is not considered impaired, and the second step of the impairment test is unnecessary. If the carrying amount of a reporting unit exceeds its fair value, the second step of the goodwill impairment test would be performed to measure the amount of impairment loss to be recorded, if any. The Company estimated the API’s fair value based on the income approach.  The Company’s conducts its’ annual impairment tests in December of each year.
  
Assured Pharmacy consists of a management services holding company (“APHY”) and four operating pharmacies as of the year ended December 31, 2012 and five operating pharmacies as of the year ended December 31, 2011.  In December 2006, we acquired the remaining 49% ownership of Assured Pharmacies, Inc. which is the owner of our Riverside and Santa Ana pharmacies through the TPG acquisition (“API”).  The two API pharmacies operate in the same metropolitan area and have operating synergies and are viewed as one reportable unit by management while each of the remaining pharmacies and APHY constitute a reportable unit that is a component of Assured’s single operating segment. In December 2012, the Company consolidated the operations of our Santa Ana pharmacy into our Riverside pharmacy.  The reportable units consist of APHY, API, Kirkland, Gresham and December for the years ended December 31, 2012 and 2011.

The Company’s goodwill of $697,766 as of December 31, 2012 and 2011 is associated with the API pharmacies acquisition in 2006 and is recorded only at the API reporting unit.  The goodwill was a result of the purchase price in excess of the identifiable assets and liabilities related to the acquisition of the minority ownership in these two pharmacies.

Management estimated the fair value of the API reporting unit using the income approach by preparing a discounted cash flow analysis.  The impairment analysis for management’s assessment of goodwill for 2012 and 2011 used a baseline trend from prior fiscal years.  Management then considered the historical trends and made estimates on future years’ growth in a cash flow projection analysis to assess the API goodwill for impairment.  Since the business is primarily based on repeat patients, management also considered the most recent patient and store specific monthly trends.  The resulting forecasted growth rates did not vary significantly from historical levels.  Additionally, management performed a sensitivity analysis by preparing an additional discounted cash flow model assuming a 3% growth rate to approximate the inflation rate which did not result in goodwill impairment. Management then averaged the two scenarios to determine the final estimated fair value of the reporting unit.

The financial condition of the overall Company has negatively impacted the operating results of the reporting units by constraining revenue growth, decreasing gross profit margins and increasing operating expenses.  Despite these financial constraints, API’s operations as a stand-alone reporting unit have the historical and projected operations to be a viable business. Based on the results of the impairment testing, management believes that the fair value of the API reporting unit is substantially in excess of its carrying value and concluded that there was no impairment.
 
Common Stock Warrant Liability
 
The Company accounts for its common stock warrants under ASC 480, “Distinguishing Liabilities from Equity,” which requires any financial instrument, other than an outstanding share, that, at inception, embodies an obligation to repurchase the issuer’s equity shares, or is indexed to such an obligation, and it requires or may require the issuer to settle the obligation by transferring assets, would qualify for classification as a liability. The guidance required the Company’s outstanding warrants from convertible debenture private placements in the years ended December 31, 2012, 2011 and 2010 to be classified as liabilities and to be fair valued at each reporting period, with the changes in fair value recognized as a change in fair value of warranty liability in the Company’s consolidated statements of operations. Specifically, the warrants issued in connection with convertible debenture private placements in December 2010, throughout the years 2011 and 2012, grant the warrant holder certain anti-dilution protection which provide exercise price adjustments in the event that any common stock or common stock equivalents are issued at an effective price per share that is less than the exercise price per share.  Upon exercise or expiration of the warrant, the fair value of the warrant at that time will be reclassified to equity from a liability.  

 
 
 
 
- 40 -

 
 
 
 
New Accounting Standards

In May 2011, the FASB issued Accounting Standards Update (“ASU”) 2011-04, “Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs,” which amends ASC 820, “Fair Value Measurement.” The amended guidance changes the wording used to describe many requirements in U.S. GAAP for measuring fair value and for disclosing information about fair value measurements. Additionally, the amendments clarify the FASB’s intent about the application of existing fair value measurement requirements. The guidance provided in ASU No. 2011-04 is effective for interim and annual periods beginning after December 15, 2011 and is applied prospectively. The provisions are effective for our year ended December 31, 2012. We do not expect the adoption of these provisions to have a significant effect on our consolidated financial statements.
 
In September 2011, the FASB issued Accounting Standards Update (“ASU”) No. 2011-08 “Intangibles—Goodwill and Other” intended to simplify goodwill impairment testing. Entities will be allowed to perform a qualitative assessment on goodwill impairment to determine whether it is more likely than not (defined as having a likelihood of more than  50 percent) that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. The amendments in this ASU are effective for goodwill impairment tests performed in interim and annual periods for fiscal years beginning after December 15, 2011, with early adoption permitted. In addition, Topic 350 also requires an entity to perform a “Step 2” for reporting units with zero or negative carrying values. The adoption of ASU 2011-08 did not have an impact on our consolidated results of operations or financial conditions.
 
 
ON ACCOUNTING AND FINANCIAL DISCLOSURE
 
On February 8, 2013, the Company, at the direction of the Board of Directors, of the Company dismissed UHY, LLP as the Company’s independent registered public accounting firm, effective February 8, 2013. During the years ended December 31, 2011 and 2010 and through the date of the dismissal were no (1) disagreements with UHY on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreements if not resolved to its satisfaction would have caused UHY to make reference in its reports on the Company’s consolidated financial statements for such years to the subject matter of the disagreement, or (2) “reportable events,” as such term is defined in Item 304(a)(1)(v) of Regulation S-K.
 
The audit reports of  UHY on the consolidated financial statements of the Company, as of and for the years ended December 31, 2011 and 2010, did not contain any adverse opinion or disclaimer of opinion, nor were they qualified or modified as to audit scope, or accounting principles.
 
Effective February 8, 2013, the Company’s Board of Directors approved the engagement of BDO USA, L.L.P.  (“BDO”) as the Company’s new independent registered public accounting firm to audit the Company’s consolidated financial statements for the year ended December 31, 2012.
 
During the Company’s two most recent fiscal years and the subsequent interim period preceding BDO’s engagement, neither the Company nor anyone on behalf of the Company consulted with BDO regarding the application of accounting principles to any specific completed or contemplated transaction, or the type of audit opinion that might be rendered on the Company’s financial statements, and BDO did not provide any written or oral advice that was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue or any matter that was the subject of a “disagreement” or a “reportable event,” as such terms are defined in Item 304(a)(1) of Regulation S-K.

There are no disagreements with BDO on accounting and financial disclosure.

 
 
 
 
 
 
- 41 -

 
 
 
 
 
Board of Directors and Executive Officers
 
The following table sets forth the names, positions and ages of our directors and executive officers as of the date of this prospectus. Our directors are typically elected at each annual meeting and serve for one year and until their successors are elected and qualify. Officers are elected by our board of directors and their terms of office are at the discretion of our board.
 
Name
 
Age
 
Position(s)
Robert DelVecchio
 
48
 
Chief Executive Officer & Director
Mike Schneidereit
 
39
 
Chief Operating Officer
Brett Cormier
 
45
 
Chief Financial Officer
Thomas Bilodeau III
 
45
 
Director
Craig Eagle
 
46
 
Director
Darshan Sheth
 
37
 
Director

 The following is information about the experience and attributes of the members of our board of directors as of the date of this prospectus.  The experience and attributes discussed below provide the reasons that these individuals were selected for board membership, as well as why they continue to serve on the board.
 
Board of Directors
 
Robert DelVecchio. Mr. DelVecchio has been our Chief Executive Officer and a director since February 2005.  In addition to leading our organization, Mr. DelVecchio’s responsibilities also include sales, investor relations, business development and fund raising. Since 1995, Mr. DelVecchio has acted as Chief Executive Officer and President of Brockington Securities, Inc., a broker-dealer and member of the FINRA from May 1995 - June 2010.  Mr. DelVecchio is also a member of the board of directors of IGHL Foundation, a charitable organization that provides programs, services and support for people with developmental disabilities in the New York tri-state region.  Mr. DelVecchio’s broad experience in capital markets, experience in leading start-up businesses, and his knowledge of our Company as our longest serving director, led to the Company’s conclusion he should serve as a director of our Company.
 
Thomas Bilodeau, III. Mr. Bilodeau became a director in June 2009.  Mr. Bilodeau is a member/shareholder of Rich May, P.C., Attorneys and Counselors at Law, where he concentrates on corporate, commercial, and securities law. Mr. Bilodeau also chairs the firm’s Investment Management Practice.  Mr. Bilodeau has been with the firm full time as a lawyer since September of 1996.  Mr. Bilodeau sits on the board of directors of Astonfield Renewable Resources, Ltd., a Malta company and is actively involved as a member of the Board of Medicines for Humanity, a 501(c)(3) charity combating child-mortality internationally.  He is a member of the American, Massachusetts and Boston Bar Associations.   Mr. Bilodeau’s extensive and broad experience in corporate and securities law, led to the Company’s conclusion he should serve as a director of our Company.

 Craig Eagle. M. D.   Dr. Craig Eagle became a director in June 2009.  Dr. Craig Eagle has served as vice president of Strategic Alliances and partnerships for the Global Oncology business unit at Pfizer since January 2009 where he is involved in nurturing business to business interactions and partnerships. As part of that role, he has been leading the integration of the Pfizer/Wyeth oncology businesses and combining the oncology portfolios. From 2007 to 2008, Dr. Eagle headed up the global oncology medical and outcomes research group for Pfizer. In this position, he oversaw the medical and outcomes programs of Pfizer’s oncology business. Dr. Eagle is a member of the oncology business unit leadership team. Dr. Eagle initially joined Pfizer Australia in 2001 as part of the medical group. In Australia, his role involved leading and participating in scientific research, regulatory and pricing and reimbursement negotiations for several compounds.  Dr. Eagle’s background as a medical doctor, his extensive experience in healthcare, pharmaceuticals, and insurance reimbursement, particularly his experience in pain management and developing new businesses, led to the Company’s conclusion he should serve as a director of our Company.
 
 
 
 
 
 
 
- 42 -

 

 
 
Darshan Sheth. Mr. Sheth became a director in June 2009.  Mr. Sheth has served as Chief Financial Officer for Mosaic Capital Advisors, the Mosaic Private Equity family of funds and the Astonfield Group of Companies, Inc. since 2007.  Mr. Sheth’s previous position was the head of Finance and Treasurer at CBay Systems, Ltd. (now listed as MModal) one the largest transcription service providers in the United States.  Mr. Sheth joined CBay in 1999 as a startup company and played an integral role in growing the Company both organically and through acquisitions to annual revenues in excess of $60M.  Mr. Sheth has successfully cleared the Uniform Certified Public Accountant examination in the United States and is also a Chartered Accountant (A.C.A.).   Mr. Sheth’s extensive experience in accounting, finance, and capital markets, particularly his experience in start up businesses in the healthcare industry, led to the Company’s conclusion he should serve as a director of our Company.
 
Executive Officers
 
The following is information about our executive officers as of the date of this prospectus.
 
Robert DelVecchio. Mr. DelVecchio has been our Chief Executive Officer and a director since February 2005. See “Board of Directors” above.
 
Mike Schneidereit.  Mr. Schneidereit joined us in October 2008 and became our Chief Operating Officer in May 2009.   Mr. Schneidereit’s responsibilities include pharmacy operations, sales, purchasing and information technology. From March 2006 to 2008, Mr. Schneidereit was the Director of Operations for SureHealth, LLC where he was responsible for the management of their specialty pharmacy line of business and corporate information technology.
 
Brett Cormier, C.P.A. Mr. Cormier joined us in September 2008 and became our Chief Financial Officer in May 2009.  Mr. Cormier is responsible for the management of the finance, accounting, human resources functions and our overall corporate administration. From February 2007 to August 2008, Mr. Cormier served as Chief Financial Officer of Sleep Holdings, Inc. and previously served as Vice President of Finance and Corporate Controller for First Broadcasting, LLC from August 2006 to January 2007.  From February 2003 to July 2007, Mr. Cormier served as Vice President of Finance for Holigan Investment Group, Ltd.
 
Involvement in Certain Legal Proceedings
 
Mr. DelVecchio and Brockington Securities, Inc. (“Brockington”) have each within the last ten years been the subject of sanctions imposed by Financial Industry Regulatory Authority (“FINRA”).  Brockington previously operated as a broker-dealer and during this time Mr. DelVecchio acted as a broker at Brockington and also served as Brockington’s President and Chief Executive Officer.  On April 29, 2011, Mr. DelVecchio consented to sanctions permanently barring him from association with any FINRA member based on allegations that he failed to appear for an on-the-record interview requested by FINRA.  On July 28, 2009, Mr. DelVecchio was censured, fined an undisclosed amount and ordered to undergo further training related to allegations that Brockington, through Mr. DelVecchio, failed to detect, investigate and report suspicious activity in trading accounts, prepare reports related thereto and conduct an anti-money laundering (“AML”) audit for 2007.
 
On January 14, 2010, Brockington was censured, fined $24,000 and ordered to have all of its employees undergo further training related to allegations that it failed to implement an AML program, detect, investigate and report suspicious activity in trading accounts and conduct an AML audit in one year.  Brockington’s failure to pay the foregoing fine resulted in its expulsion from FINRA membership on July 8, 2010.  On May 5, 2006, Brockington was censured, fined $15,000 and ordered to revise its written supervisory procedures related to allegations that it failed to transmit last sale reports in accordance with applicable rules.  On August 29, 2005, Brockington was censured and fined $7,500 related to allegations that an escrow agreement, in connection with a private offering, did not adequately ensure procedures regarding the transmittal and/or return of funds received from such offering.
 
 
 
 
 
 
 
- 43 -

 
 
 
 
 
Summary Compensation Table
 
The following table presents information about the compensation of our “Named Executive Officers,” as such term is defined in SEC rules.  For fiscal 2011 and 2012, our Named Executive Officers include our Chief Executive Officer, our Chief Financial Officer and our Chief Operating Officer.
 
Summary Compensation Table
 
Name
Year
Salary
($)
 
Bonus
($)
Stock
Awards
($) (1)
Option
Awards
($) (1)
All Other
Compensation
($)
 
Total
($)
               
Robert DelVecchio
Chief Executive Officer
2012
2011
247,115
175,692
-
-
-
-
72,796
-
-
-
319,911
175,692
               
Mike Schneidereit
Chief Operating Officer
2012
2011
175,000
175,692
-
-
-
-
72,796
-
-
-
247,796
176,692
               
Brett Cormier
Chief Financial Officer
2012
2011
175,000
175,692
-
-
-
-
72,796
-
-
-
247,796
175,692
               
(1)  
The amounts in the table reflect the grant date fair value of options and stock awards to the named executive officer in accordance with Accounting Standards Codification Topic 718.  The ultimate values of the options and stock awards to the executives generally will depend on the future market price of our common stock, which cannot be forecasted with reasonable accuracy. The actual value, if any, that an optionee will realize upon exercise of an option will depend on the excess of the market value of the common stock over the exercise price on the date the option is exercised.  Refer to the assumptions used in applying the Black-Scholes option pricing model to determine the fair value of awards granted in Note 6, “Stock Based Compensation” to financial statements for years ended December 31, 2012 and 2011.See the “Outstanding Equity Awards at Fiscal Year-End” table below for information regarding all outstanding awards
 
Compensation Components
 
Salary.  We compensate our executive officers for their service by payment of salary, which is set in each of the named executive officer’s employment agreement discussed below.

 Discretionary Bonuses. Our board of directors has the authority and discretion to award performance-based compensation to our executives if it determined that a particular executive has exceeded his objectives and goals or made a unique contribution to us during the year, or other circumstances warrant. There were no discretionary bonuses paid to our Named Executive Officers during fiscal 2012.

 Stock and Stock Option Awards.  Stock and stock option awards are determined by the board of directors based on numerous factors, some of which include responsibilities incumbent with the role of each executive and tenure with us.

 At no time during the last fiscal year was any outstanding option repriced or otherwise modified.  There was no tandem feature, reload feature, or tax-reimbursement feature associated with any of the stock options we granted to our executive officers or otherwise.
 
 
 

 
 
- 44 -

 
 
 
Employment Agreements; Termination of Employment and Change-in-Control Arrangements
 
Employment Agreements
 
In 2009, we entered into employment agreements with the Named Executive Officers. Each of these agreements was replaced by new employment agreements with the Named Executive Officers in May 2012. Under these agreements, Mr. DelVecchio receives a base salary of $250,000 and Messrs. Cormier and Schneidereit each receive a base salary of $225,000.  In addition, Messrs. DelVecchio, Cormier and Schneidereit each are eligible for a cash performance bonus up to 75% of their annual base salary. In addition, Messrs. DelVecchio, Cormier and Schneidereit each were granted 175,000 stock options under the 2012 Incentive Compensation Plan.  These stock options vest immediately and have a strike price of $0.60 with an exercise period of ten (10) years.  Termination benefits under the agreements are triggered if we terminate an agreement without cause or if a covered employee terminates his employment after the employee’s base salary is reduced by 5% or more, in each instance, if the employee notifies us in writing within 30 days of the change that he objects to the change and we do not rescind the change within 30 days of receiving the employee’s notice. This trigger events was chosen to help retain these executive officers and to assure these executive officers that they could apply their full attention to our business. The employment agreements were designed to promote stability and continuity of senior management.
 
Termination benefits under the employment agreements include: (i) any earned but unpaid salary; (ii) one year base salary; (iii) 150% of target bonus; (iv) one year company contributions to deferred compensation plans; and (v) up to one year COBRA premiums. Except for any earned but unpaid salary at the time of termination, benefits under the employment agreements would be paid out monthly over a one-year period.  Payment of termination benefits is contingent on the employee executing a release and complying with non-disclosure, non-competition and non-solicitation covenants for a period of one year following termination of employment.
 
Outstanding Equity Awards
 
Fiscal Year-Ended December 31, 2012
 
The following table presents information concerning the outstanding equity awards for the Named Executive Officers as of December 31, 2012, each of which was granted to the Named Executive Officers during fiscal 2012:
 
Option Awards
 
Name
 
Number of
Securities
Underlying
Unexercised
Options (#)
Exercisable
 
Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable
 
Equity Incentive
Plan Awards:
Number of Securities
Underlying
Unexercised
Unearned Options
(#)
 
Option
Exercise
Price
($)
 
Option
Expiration
Date
                     
Robert DelVecchio
Chief Executive Officer
 
375,001
175,000
 
124,999
-
 
-
-
 
$0.68
$0.60
 
04/01/2021
05/08/2022
                     
Mike Schneidereit
Chief Operating Officer
 
208,333
175,000
 
69,445
-
 
-
-
 
$0.68
$0.60
 
04/01/2021
05/08/2022
                     
Brett Cormier
Chief Financial Officer
 
208,333
175,000
 
69,445
-
 
-
-
 
$0.68
$0.60
 
04/01/2021
05/08/2022
                     
 
 
 
 
 
 
- 45 -


 
 
 
Stock Option Plan

 Historically, our board of directors granted stock options to management primarily as part of the hiring and recruitment process.  The issuance of these stock options is intended to provide incentives that will attract and retain the best available employees.  These purposes may be achieved through the grant of non-qualified stock options, incentive stock options, stock appreciation rights, restricted stock awards, performance stock awards and phantom stock awards.
 
Awards may vest, in time, upon the occurrence of one or more events or by the satisfaction of performance criteria, or any combination. To the extent that awards are performance based, they may be based on one or more criteria, including (without limitation) earnings, cash flow, revenues, operating income, capital reissues, or other quantifiable company, customer satisfaction or market data, or any combination.
 
2012 Incentive Compensation Plan
 
In May 2012 we adopted the Assured Pharmacy, Inc. 2012 Incentive Compensation Plan (the “2012 Incentive Plan”). The 2012 Incentive Plan is intended to provide incentives that will attract and retain the best available directors, employees and appropriate third parties who can provide us with valuable services.  These purposes may be achieved through the grant of non-qualified stock options, incentive stock options, stock appreciation rights, restricted stock awards, performance stock awards and phantom stock awards.
 
The 2012 Incentive Plan permits the grant of awards that may deliver up to an aggregate of 1,667,667 shares of common stock, further subject to limits on the number of shares that may be delivered pursuant to incentive stock options, on the shares that may be delivered on the awards to any individual in a single year and on the number of shares that may be delivered on certain awards that are performance-based awards, within the meaning of Section 162(m) of the Internal Revenue Code.  Awards may vest, in time, upon the occurrence of one or more events or by the satisfaction of performance criteria, or any combination. To the extent that awards are performance based, they may be based on one or more criteria, including (without limitation) earnings, cash flow, revenues, operating income, capital reissues, or other quantifiable company, customer satisfaction or market data, or any combination. In addition to common stock, awards may also be made in similar securities whose value is derived from our common stock.
 
Awards with respect to which grant, vesting, exercisability or payment depend on the achievement of performance goals and awards that are options or stock appreciation rights granted to officers and employees will be intended to satisfy the requirements for “performance-based compensation” under Section 162(m) of the Internal Revenue Code. The 2012 Incentive Plan will be administered by the board of directors.
 
Option Exercises and Stock Vested in Fiscal 2012
 
No options were exercised by Named Executive Officers or stock that vested in fiscal 2012.
 
Pension Benefits
 
None of our Named Executive Officers participated in any qualified or nonqualified defined-benefit pension plans as of December 31, 2012.
 
Compensation of Directors
 
In May 2012, our board of directors approved the following compensation to be paid to non-employee directors:
 
·     
$1,500 for each board meeting attended in person and $500 for each board meeting attended by telephone; and
·     
$1,500 for each committee meeting attended in person and $500 for each committee meeting attended by telephone.
 
 For the fiscal year ended December 31, 2012, no compensation was earned or paid to the Company’s non-employee directors.
 

 
 
- 46 -

 
 
 
 
 
Transactions with related parties and their affiliates are made in the ordinary course of business on substantially the same terms and conditions, including interest rates and collateral, as those prevailing at the same time for comparable transactions with other unaffiliated third parties, and do not, in the opinion of management, involve more than normal credit risk or present other unfavorable features.
 
Mosaic Group
 
Mosaic Capital Advisors, LLC, together with its affiliated entities Mosaic Financial Services (“MFS”), LLC, Mosaic Private Equity Fund, L.P., Mosaic Capital Management, Ltd. and its affiliated accredited investor, Joseph McDevitt (collectively, “Mosaic”), were the beneficial owners of approximately 56.9%, 96.2%, and 75.4% of the our common stock, Series A Convertible Preferred Stock and Series B Convertible Preferred Stock, respectively, as of  May 31, 2013.  Under the terms of our Certificate of Designations, Preferences and Rights of the Series A Convertible Preferred Stock and Series B Convertible Preferred Stock, Mosaic, due to its ownership interest of our Series A Convertible Preferred Stock, has the right to elect four directors to our Board and partially exercised this right by appointing Messrs. Sheth, Bilodeau and Eagle to serve as directors.  Mr. Bilodeau is a member/shareholder of Rich May, P.C., Attorneys and Counselors at Law, which provides legal services to Mosaic.
 
In September 2012, the holders of a majority of the Series A and C Preferred stock consented to a partial anti-dilution adjustment in conversion price per share to $0.90 per share in the event of the minimum offering being achieved in a private placement of common stock and warrants.  In February 2013, the minimum offering was achieved resulting in an adjusted conversion price of $0.90 per share for a total of 1,567,898 and 4,356,671common shares on an as converted basis for Series A Convertible Preferred Stock and Series B Convertible Preferred Stock, respectively subject to adjustment for stock dividends, stock splits and related distributions.
 
In July 2010, we completed a sale in a private transaction to Joseph McDevitt, an accredited investor affiliated with Mosaic, for a 10.0% convertible debenture for an aggregate principal amount of $500,000 (before deducting expenses and fees related to the private transaction) due in July 2012.  The debenture is convertible into shares of the our Series A Convertible Preferred Stock at an initial conversion price of $1,000 per share and subject to adjustments, and each share of Series A Preferred is convertible into 695 shares of our common stock for a total of 347,500 common shares on an as converted basis (subject to adjustment for certain dilutive transactions).  Interest on the debenture is payable quarterly in shares and is calculated based on the higher of the average stock price for the five (5) prior trading days or $1.80 per common share.  As of May 31, 2013 , no principal payments have been made on the debenture since issuance and a total of 46,474 common shares were issued for payment of interest due.  In July 2012, we entered into an amendment to the debenture agreement, in which the term of the debenture was modified and extended for a period of one year.  As consideration for the extension, the interest rate for the debenture was increased from 10.0% to 16.0%. In September 2012, the holders of a majority of the Series A and C Preferred stock consented to a partial anti-dilution adjustment in conversion price per share to $0.90 per share in the event of the minimum offering being achieved in a private placement of common stock and warrants.  In February 2013, the minimum offering was achieved resulting in an adjusted conversion price of $0.90 per share for a total of 555,556 common shares on an as converted basis, subject to adjustment for stock dividends, stock splits and related distributions.
 
Robert DelVecchio
 
Robert DelVecchio, our Chief Executive Officer and a member of our board of directors, also serves as President and Chief Executive Officer of Brockington Securities, Inc. (“Brockington”).
 
In March 2009, we entered into a Revolving Line of Credit Agreement with Brockington for a credit limit of $300,000 with a term of one year bearing interest of 12.0% per annum. Under the terms of the line of credit, we could request for advance from time to time, provided, however, any requested advance will not, when added to the outstanding principal advanced of all previous advances, exceed the credit limit. We could repay accrued interest and principal at any time, however no partial repayment would relieve us of the obligation of the entire unpaid principal together with any accrued interest and other unpaid charges.  There are no financial covenants that we are required to maintain.
 
The line of credit was subsequently extended.  The latest extension occurred on June 22, 2012, pursuant to a Modification and Extension Agreement to the Revolving Line of Credit Agreement dated March 10, 2009, in which the term of the loan was modified and the maturity date of the loan was extended to June 30, 2014 by mutual consent.  In November 2012, the Modification Agreement to the Revolving Line of Credit Agreement dated March 10, 2009, in which the credit limit was modified the credit limit was increased from $300,000 to $500,000. All additional terms of the loan remain unchanged and we are not in violation of any provisions of the line of credit.
 
As of May 31, 2013, the outstanding balance on the line of credit was $423,000 with remaining availability of $77,000 and the largest aggregate amount of principal outstanding on the loans was $453,000. Interest paid on the loan from origination through May 31, 2013 was $94,931.  As of May 31, 2013, we had drawn a total of $1,958,540 and repaid a total of $1,535,540.
 
Haresh Sheth
 
Haresh Sheth, former President and a member of our board of director and the beneficial owner of approximately 13.9% of our common stock.  On July 18, 2011, Haresh Sheth resigned his position as President and member of our board of directors.  There were no severance costs associated with his resignation.  Also on July 18, 2011, we entered into a Consulting Agreement with Mr. Sheth under which he will provide us with consulting services for a term of one year in exchange for 225,000 shares of restricted stock, which were fully vested on the date of issuance.   The market value of our common stock on July 18, 2011, the date of issuance, was $1.20 per share.
 
 
 
 
 

 
 
- 47 -

 
 
 
 
Dr. Craig Eagle
 
Dr. Craig Eagle, a member of our board of directors, also serves as manager of CJE Holdings, LLC.
 
On February 9, 2010, we engaged CJE Holdings, LLC to act a non-exclusive advisor to provide medical consulting services relating to, among other things, pain management for a period of two years.  The consideration for the services was 55,556 restricted shares of our common stock payable in four equal installments (every 6 months).  The market value of our common stock on February 9, 2010 was $2.34 per share.  As of May 31, 2013 , we had issued a total of 41,667 shares in accordance with this engagement.
 
Pinewood Trading Company
 
Pinewood Trading Company (“Pinewood”) was the beneficial owner of approximately 31.7% and 11.5% of our common stock and Series B Convertible Preferred Stock, respectively as of May 31, 2013.
 
In September 2012, the holders of a majority of the Series A and C Preferred stock consented to a partial anti-dilution adjustment in conversion price per share to $0.90 per share in the event of the minimum offering being achieved in a private placement of common stock and warrants.  In February 2013, the minimum offering was achieved resulting in an adjusted conversion price of $0.90 per share for a total of 666,668 common shares on an as converted basis for Series B Convertible Preferred Stock, respectively  subject to adjustment for stock dividends, stock splits and related distributions.
 
On November 30, 2011, we completed a sale in a private transaction to Pinewood of a 16.0% senior convertible debenture for an aggregate principal amount of $50,400 (before deducting expenses and fees related to the private transaction) with principal reductions of $12,600 due in November 2012 and February 2013, and $25,200 due May 2013 plus any unpaid interest.  We have the option to pay all or part of the November 2012 principal reductions with shares of our common stock, subject to certain equity conditions, as defined in the debenture.  These equity conditions include, among others, our compliance with honoring all conversions and redemptions, payment of all liquidated damages of the debenture, an effective registration to allow for resale of the common shares and the ability to resell such common pursuant to Rule 144.  The debenture is convertible into shares of our common stock at an initial conversion price of $1.26 per share for a total of 40,000 common shares on an as converted basis (subject to adjustment for certain dilutive transactions).  As of May 31, 2013 , we paid $3,360 in interest due on this debenture.  In June 2012, the debenture was amended and the maturity date was extended to May 30, 2014. As part of the foregoing amendment, the exercise period of the warrants was extended from three years to five years.
 
As part of the private transaction on November 30, 2011, Pinewood also received warrants to purchase 48,000 shares of our common stock.  These warrants were fully vested on the date of issuance and are exercisable for a period of three years from the date of issuance at an initial exercise price of $1.512, subject to adjustment.  The investor may exercise the warrant on a cashless basis only if the shares of common stock underlying the warrant are not then registered pursuant to an effective registration statement.  The outstanding warrants are subject certain anti-dilution protection clauses which provide exercise price adjustments in the event that any common stock or common stock equivalents are issued at an effective price per share that is less than the exercise price per share.  From September 2012 through February 2013, all of the investors in 2011 private placements consented to a partial anti-dilution adjustment in conversion price per share to $0.90 per share in the event of the minimum offering being achieved in a private placement of common stock and warrants.  In February 2013, the minimum offering was achieved resulting in an adjusted conversion price of $0.90 per share for a total of 56,000 common shares on an as converted basis, subject to adjustment for stock dividends, stock splits and related distributions and increase to 80,640 warrants at an exercise price of $0.90.
 
On July 9, 2012, we entered into a consulting agreement with Jack Brooks, managing partner of Pinewood Trading Company.  We issued 65,000 restricted common shares as payment in full for financial advisory services rendered to us.  The market value of the stock on July 9, 2012, the date of issuance, was $0.51 per common share.
 
In February 2013, the Company completed a sale in a private placement to Pinewood for twenty (20) common stock units for a total of 769,240 shares of common stock at an aggregate purchase price of $500,000 (before deducting expenses and fees related to the private placement).   The net proceeds of the private placement were used to pay down our outstanding balance with our primary wholesaler.  As part of the private placement, the investors also received warrants to purchase an aggregate of 769,240 shares of the Company’s common stock.
 
H.D. Smith Wholesale Drug Co.
 
H.D. Smith Wholesale Drug Co. (“H.D. Smith”) is our primary drug wholesaler and was the beneficial owner of approximately 12.5% and 100% of our common stock and Series C Convertible Preferred Stock, respectively as of May 31, 2013.
 
During the years ended December 31, 2012 and 2011, we purchased approximately $10.1 million and $10.7 million, respectively, or 92% and 80%, respectively, of our prescription drug inventory from H.D. Smith. At December 31, 2012 and 2011, accounts payable to H.D. Smith were approximately $3.6 million and $2.6 million, respectively.
 
In September 2010, we entered into a secured loan agreement with H.D. Smith. Under the terms of this agreement, we received a two (2) year loan of $400,000 with an adjustable interest rate of prime plus 3.00% per annum, with interest payable monthly. Monthly payment requirements are $5,000 per month for eight consecutive months, followed by eight consecutive monthly principal reductions of $10,000, followed by seven consecutive monthly principal reductions of $15,000, with remaining principal and interest due September 1, 2012. The proceeds from the note were simultaneously exchanged for $400,000 in outstanding invoices due to H.D. Smith. In February 2013, the Company entered into a secured loan agreement with our primary wholesaler. Under the terms of this agreement, the Company received a one (1) year loan of $3,828,527 with an interest rate of 6.25% per annum, with interest payable monthly. Monthly payment requirements are $27,000 per month for four consecutive months, followed by four consecutive monthly principal reductions of $37,000, followed by three consecutive monthly principal reductions of $42,000, with remaining principal and interest due February 1, 2014. The proceeds from the note were simultaneously exchanged for $3,534,793 in outstanding vendor invoices and $293,734 in outstanding secured note payable. The note is secured by all of the assets of the Company and its subsidiaries through UCC-1 filings.  As of February 1, 2013, the Company paid $52,148 in interest and $106,266 on the September 2010 loan.  As of May 31, 2013, the Company paid $58,158 in interest on the February 2013 loan and the outstanding principal balance is $3,801,379.
 
 
 
 
 
 
- 48 -

 
 
 
 
Baruch Halpern Revocable Trust
 
Baruch Halpern Revocable Trust, together with Halpern Capital, Inc. (“HC”), was the beneficial owner of approximately 13.5% of our common stock as of May 31, 2013.
 
In April 2010, we entered into a secured loan agreement with Baruch Halpern Revocable Trust, an accredited investor, in a private transaction. The loan was secured by 483,871 shares we held in Generex Biotechnology Corporation restricted common stock. Under the terms of this loan agreement, we received a loan of $250,000 at an interest rate of 12% per annum, with interest of $30,000 payable in advance with the principal due in April 2011 at maturity.  In addition, we issued 27,778 shares of our common stock as additional compensation. The pledged collateral was subsequently released by the lender in September 2010.
 
On June 22, 2011, the outstanding principal loan balance of $250,000 was converted into a 16.0% senior convertible debenture through a private transaction for an aggregate principal amount of $250,000, which matures on June 22, 2012. The debenture is convertible into shares of our common stock at an initial conversion price of $1.26 per share for a total of 198,413 common shares on an as converted basis, subject to adjustment for stock dividends, stock splits and related distributions.  As part of the private transaction, Baruch Halpern Revocable Trust also received a warrant to purchase 238,095 shares of our common stock.  The warrant was fully vested on the date of issuance and is exercisable for a period of three years from the date of issuance at an initial exercise price of $1.512, subject to adjustment for stock dividends, stock splits and related distributions.  Baruch Halpern Revocable Trust may exercise the warrant on a cashless basis only if the shares of common stock underlying the warrant are not then registered pursuant to an effective registration statement.  The outstanding warrants are subject to certain anti-dilution protection clauses which provide exercise price adjustments in the event that any common stock or common stock equivalents are issued at an effective price per share that is less than the exercise price per share.  As part of the foregoing amendment, the exercise period of the warrants was extended from three years to five years.  From September 2012 through February 2013, all of the investors in 2011 private placements consented to a partial anti-dilution adjustment in conversion price per share to $0.90 per share in the event of the minimum offering being achieved in a private placement of common stock and warrants.  In February 2013, the minimum offering was achieved resulting in an adjusted conversion price of $0.90 per share for a total of 277,778 common shares on an as converted basis, subject to adjustment for stock dividends, stock splits and related distributions and increase to 400,000 warrants at an exercise price of $0.90.
 
On June 1, 2011, we entered into a consulting agreement with HC, a registered broker-dealer engaged in the business of providing capital raising and advisory services.   We issued 90,000 restricted common shares as payment in full for financial advisory services rendered to us.  The market value of the stock on June 1, 2011, the date of issuance, was $1.35 per common share.  In June 2012, the debenture was amended to extend the maturity date to June 22, 2013. As part of the foregoing amendment, the exercise period of the warrants was extended from three years to five years.
 
Hillair Capital Investments, LP
 
Hillair Capital Investments, LP (“HCI”) was the beneficial owner of approximately 32.6 % of our common stock as of  May 31, 2013 .
 
On May 16, 2011, we completed a sale in a private transaction to HCI of a 16.0% senior convertible debenture for an aggregate principal amount of $500,000 (before deducting expenses and fees related to the private transaction) with principal reductions of $125,000 due in June 2012 and September 2012, and $250,000 due December 2012 plus any unpaid interest.  The proceeds from the private transaction included conversion of an outstanding $300,000 12.5% senior convertible debenture held by HCI resulting in our receipt of gross cash proceeds of $200,000 from this transaction. We have the option to pay all or part of the June 2012 principal reductions with shares of our common stock, subject to certain equity conditions, as defined in the debenture.  These equity conditions include, among others, our compliance with honoring all conversions and redemptions, payment of all liquidated damages of the debenture, and maintaining an effective registration statement to allow for resale of the common shares or providing an opinion of counsel attesting to HCI’s ability to resell such common pursuant to Rule 144.  The debenture is convertible into shares of our common stock at an initial conversion price of $1.26 per share for a total of 396,826 common shares on an as converted basis (subject to adjustment for certain dilutive transactions).  As of May 31, 2013 , we paid $90,222 in interest in cash and $20,000 in common stock at a rate of $0.20 per share.  As part of the private transaction, HCI also received warrants to purchase 476,191 shares of our common stock.  The warrants were fully vested on the date of issuance and are exercisable for a period of three years from the date of issuance at an initial warrant exercise price of $1.512, subject to adjustment.  HCI may exercise the warrant on a cashless basis only if the shares of common stock underlying the warrant are not then registered pursuant to an effective registration statement.  The outstanding warrants are subject certain anti-dilution protection clauses which provide exercise price adjustments in the event that any common stock or common stock equivalents are issued at an effective price per share that is less than the exercise price per share.  In September 2012, the debenture was amended to extend the maturity date to December 1, 2013. As part of the foregoing amendment, the exercise period of the warrants was extended from three years to five years.  From September 2012 through February 2013, all of the investors in 2011 private placements including HCI, consented to a partial anti-dilution adjustment in conversion price per share to $0.90 per share in the event of the minimum offering being achieved in a private placement of common stock and warrants.  In February 2013, the minimum offering was achieved resulting in an adjusted conversion price of $0.90 per share for a total of 555,556 common shares on an as converted basis, subject to adjustment for stock dividends, stock splits and related distributions and increase to 800,001 warrants at an exercise price of $0.90.
 
 
 

 
 
- 49 -

 
 
 
 
 
On August 22, 2011, we completed a sale in a private transaction to HCI for a 16.0% senior convertible debenture for an aggregate principal amount of $100,000 (before deducting expenses and fees related to the private transaction) with principal reductions of $25,000 due in June 2012 and September 2012, and $50,000 due December 2012 plus any unpaid interest.  We have the option to pay all or part of the June 2012 principal reductions with shares of our common stock, subject to certain equity conditions, as defined in the debenture.  These equity conditions include, among others, our compliance with honoring all conversions and redemptions, payment of all liquidated damages of the debenture, and either maintaining an effective registration statement  to allow for resale of the common shares or providing an opinion of counsel attesting to HCI’s ability to resell such common pursuant to Rule 144.  The debenture is convertible into shares of our common stock at an initial conversion price of $1.26 per share for a total of 79,366 common shares on an as converted basis (subject to adjustment for certain dilutive transactions).  As of May 31, 2013 , we paid $9,689 in interest in cash and $4,000 in common stock at $0.20 per share due on this debenture.   As part of the private transaction, HCI also received warrants to purchase 95,239 shares of our common stock.  The warrants were fully vested on the date of issuance and are exercisable for a period of three years from the date of issuance at an initial exercise price of $1.512, subject to adjustment.  HCI may exercise the warrants on a cashless basis only if the shares of common stock underlying the warrant are not then registered pursuant to an effective registration statement.  The outstanding warrants are subject certain anti-dilution protection clauses which provide exercise price adjustments in the event that any common stock or common stock equivalents are issued at an effective price per share that is less than the warrant exercise price per share.  In September 2012, the debenture agreement was amended to extend the maturity date to December 1, 2013.  As part of the foregoing amendment, the exercise period of the warrants was extended from three years to five years.   From September 2012 through February 2013, all of the investors in 2011 private placements including HCI, consented to a partial anti-dilution adjustment in conversion price per share to $0.90 per share in the event of the minimum offering being achieved in a private placement of common stock and warrants.  In February 2013, the minimum offering was achieved resulting in an adjusted conversion price of $0.90 per share for a total of 111,112 common shares on an as converted basis, subject to adjustment for stock dividends, stock splits and related distributions and increase to 160,002warrants at an exercise price of $0.90.
 
On November 30, 2011, we completed a sale in a private transaction to HCI for a 16.0% senior convertible debenture for an aggregate principal amount of $100,000 (before deducting expenses and fees related to the private placement) with principal reductions of $25,000 due in November 2012 and February 2013, and $50,000 due May 2013 plus any unpaid interest.  We have the option to pay all or part of the November 2012 principal reductions with shares of our common stock, subject to certain equity conditions, as defined in the debenture.  These equity conditions include, among others, our compliance with honoring all conversions and redemptions, payment of all liquidated damages of the debenture, and either maintaining an effective registration statement  to allow for resale of the common shares or providing an opinion of counsel attesting to HCI’s ability to resell such common pursuant to Rule 144.  The debenture is convertible into shares of our common stock at an initial conversion price of $1.26 per share for a total of 79,366 common shares on an as converted basis (subject to adjustment for certain dilutive transactions).  As of May 31, 2013 , we paid $6,667 in interest due in cash and $4,000 in the Company’s common stock at $0.20 per share on this debenture.  As part of the private transaction, HCI also received warrants to purchase 95,239 shares of our common stock.  The warrants were fully vested on the date of issuance and are exercisable for a period of three years from the date of issuance at an initial exercise price of $1.512, subject to adjustment. The investor may exercise the warrant on a cashless basis only if the shares of common stock underlying the warrant are not then registered pursuant to an effective registration statement.  The outstanding warrants are subject certain anti-dilution protection clauses which provide exercise price adjustments in the event that any common stock or common stock equivalents are issued at an effective price per share that is less than the warrant exercise price per share.  From September 2012 through February 2013, all of the investors in 2011 private placements including HCI, consented to a partial anti-dilution adjustment in conversion price per share to $0.90 per share in the event of the minimum offering being achieved in a private placement of common stock and warrants.  In February 2013, the minimum offering was achieved resulting in an adjusted conversion price of $0.90 per share for a total of 111,112 common shares on an as converted basis, subject to adjustment for stock dividends, stock splits and related distributions and increase to 160,002warrants at an exercise price of $0.90.
 
In July 2012, we completed a sale in a private placement to HCI for a 16.0% senior convertible debenture for an aggregate principal amount of $300,000 due December 1, 2013 (before deducting expenses and fees related to the private placement) with periodic redemptions of $75,000 due in June 2013 and September 2013, plus any unpaid interest. We have has the option to pay all or part of the June 2013 periodic redemptions with shares of our common stock, subject to certain Equity Conditions, as defined in the loan agreement.  These Equity Conditions include, among others, our compliance with honoring all conversions and redemptions, payment of all liquidated damages of the debenture, and either maintaining an effective registration statement  to allow for resale of the common shares or providing an opinion of counsel attesting to HCI’s  ability to resell such common pursuant to Rule 144.  A consent and waiver was obtained from the majority of the Series A Preferred holders, a majority of the Series B Preferred holders and all senior debenture holders as required by the agreements. The debentures are convertible into shares of our common stock at an initial conversion price of $1.26 per share for a total of 238,096 common shares on an as converted basis, subject to adjustment. As of April 30, 2013, we paid $17,467 in interest due in the Company’s common stock at $0.20 per share on this debenture.   As part of this private placement, the investor received warrants to purchase 285,715 shares of our common stock.  The warrants were fully vested on the date of issuance and are exercisable for a period of five years from the date of issuance at an initial warrant exercise price of $1.512, subject to adjustment.  The investor may exercise the warrants on a cashless basis if the shares of common stock underlying the warrants are not then registered pursuant to an effective registration statement.  The outstanding warrants are subject certain anti-dilution protection clauses which provide exercise price adjustments in the event that any common stock or common stock equivalents are issued at an effective price per share that is less than the exercise price per share.  From September 2012 through February 2013, all of the investors in 2011 private placements including HCI, consented to a partial anti-dilution adjustment in conversion price per share to $0.90 per share in the event of the minimum offering being achieved in a private placement of common stock and warrants.  In February 2013, the minimum offering was achieved resulting in an adjusted conversion price of $0.90 per share for a total of 333,334 common shares on an as converted basis, subject to adjustment for stock dividends, stock splits and related distributions and increase to 480,001 warrants at an exercise price of $0.90.
 
On May 3, 2013, Hillair Capital issued a notice of default to the 16% Senior Convertible Debentures issued on May 16, 2011, August 22, 2011, November 24, 2011 and July 19, 2012 with an aggregate principal amount of $1,000,000.
 
On June 7, 2013 CHN Partners and AQR Capital Management, LLC issued a notice of default to the 16% Senior Convertible Debentures issued on August 22, 2011 with an aggregate principal amount of $300,000.
 
 
 
 

 
 
- 50 -

 
 
 
 
CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
 
The following table sets forth information as of May 31, 2013 as to the beneficial ownership of Common Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock by: any person known to us to own beneficially more than 5% of any class; each of our directors; the individuals named in the “Summary Compensation Table” contained in this prospectus (collectively, the “Named Executive Officers”); and all of our current executive officers and directors as a group. Except as otherwise indicated below, each stockholder listed below has sole voting and investment power with respect to the shares beneficially owned by such person. The rules of the Securities and Exchange Commission consider a person to be the “beneficial owner” of any securities over which the person has or shares voting power or investment power, or any securities as to which the person has the right to acquire, within sixty days, such sole or shared power.


Name of
Beneficial
Owner (a)
Number of Shares Owned
Percentage of Beneficial Ownership
Percent of
Total Votes (d)
Common
(b)
Series A
Preferred
Series B
Preferred
Series C
Preferred
Common
(c)
Series A
Preferred
Series B
Preferred
Series C
Preferred
Before
Offering
(e)
After
Offering
(f)
Directors and Executive Officers:
                   
Robert DelVecchio
1,119,775 (1)
-
393
-
15.1%
-
7.6%
-
3.2%
2.8%
Mike Schneidereit
437,345 (2)
-
-
-
6.5%
-
-
-
*
*
Brett Cormier
437,345 (3)
-
-
-
6.5%
-
-
-
*
*
Craig Eagle
75,001  (4)
30
-
-
1.2%
2.0%
-
-
*
*
Darshan Sheth
100,000 (5)
-
-
-
*
-
-
-
*
*
Thomas Bilodeau, III
50,000
-
-
-
*
-
-
-
*
*
All  Directors and Executive Officers as a group (6 persons)
2,219,466
30
393
-
31.6%
2.0%
7.6%
-
4.8%
4.9%
                     
5% Beneficial Holders:
                   
Mosaic Capital Advisors, LLC (6)
7,891,290 (7)
1,851 (8)
3,921
-
56.9%
92.2%
75.4%
-
42.8%
37.0%
Haresh Sheth (9)
852,018 (10)
-
-
-
13.0%
-
-
-
4.1%
3.6%
Pinewood Trading Company (11)
2,502,824 (12)
-
600
-
31.7%
-
11.5%
-
10.9%
9.4%
H.D. Smith Wholesale Drug Co. (13)
902,778 (14)
-
-
813
12.5%
-
-
100%
6.2%
5.3%
Hillair Capital Investments, LP  (15)
2,938,454 (16)
-
-
-
32.6%
-
-
-
1.6%
1.3%
Baruch Halpern Revocable Trust (17)
943,369 (18)
-
-
-
13.5%
     
1.8%
1.6%
Coventry Enterprises, LLC (19)
542,223 (20)
     
7.9%
-
-
-
-
-
AQR Opportunistic Premium Offshore Fund, LP (21)
542,225 (22)
-
-
-
7.9%
-
-
-
-
-
Jonathan Green(23)
546,560 (24)
-
-
-
8.0%
-
-
-
-
-
Carl W. Grover(25)
677,735 (26)
-
-
-
9.7%
-
-
-
-
-
TriPoint Global Equities, LLC(27)
334,293 (28)
-
-
-
5.1%
-
-
-
*
*
*   
Indicates less than 1%
 
 
 
 
 
 
 
- 51 -

 
 
 
 
 
(a)  
Except as otherwise noted below, the address of each of the persons in the table is c/o Assured Pharmacy, Inc., 2595 Dallas Parkway, Suite 206, Frisco, Texas 75034.
 
(b)  
Each share of Series A, Series B and Series C Preferred Stock may be converted into shares of the Company’s common stock at the option of the holder.  The number of shares of common stock issuable upon conversion of any shares of Series A, Series B or Series C Preferred Stock is equal to the product obtained by multiplying the applicable Conversion Rate by the number of shares of Preferred Stock being converted.  The Conversion Rate is equal to the quotient obtained by dividing the Stated Value per share of Preferred Stock, which is an amount equal to $1,000, by the applicable conversion price for each share of Series A ($0.90), Series B ($0.90) or Series C Preferred Stock ($0.90).  This column includes the shares of common stock issuable upon conversion of each share of Series A, Series B and Series C Preferred Stock together will all other shares of common stock which the person has the right to acquire within sixty days.
 
(c)  
Excluding those shares of common stock which the person has the right to acquire within sixty days and based solely on the shares of common stock issued and outstanding, the percent of ownership of common stock is as follows: Robert DelVecchio (0.6%); Mike Schneidereit (0%); Brett Cormier (0%); Craig Eagle (0.7%); Darshan Sheth (1.6%); Thomas Bilodeau, III (0.8%); Mosaic Capital Advisors, LLC (5.3%); Haresh Sheth (9.8%); Pinewood Trading Company (15.1%); H.D. Smith Wholesale Drug Co. (0%); Hillair Capital Investments, LP (3.7%), Baruch Halpern Revocable Trust (4.3%); Coventry Enterprises, LLC (0%); AQR Opportunistic Premium Offshore Fund, LP (0%); Jonathan Green (0%); Carl W. Grover (0%); , and TriPoint Global Equities, LLC (2.0%).
 
(d)  
Each holder of shares of Series A, Series B and Series C Preferred Stock are entitled to such number of votes as shall be equal to the whole number of shares of Common Stock into which such holder’s aggregate number of such shares of Series A, Series B and Series C Preferred Stock are convertible.
 
(e)  
Based on a total of 6,312,828 shares of common stock outstanding, 1,516 shares of Series A Preferred Stock outstanding, 5,199 shares of Series B Preferred Stock outstanding and 813 shares of Series C Preferred Stock outstanding on May 31, 2013 and prior to any exercise of warrants into shares of common stock
 
(1)  
Includes 647,224 shares underlying stock options and 277,778 shares issuable upon conversion of Series B Preferred Stock.  Also includes 18,015 shares owned by Brockington Securities, Inc. (“Brockington”) and 158,889 common shares issuable upon conversion of Series B Preferred Stock owned by Brockington. Mr. DelVecchio exercises voting control and control over the disposition of all securities held Brockington.
 
(2)  
Includes 437,345 shares underlying stock options.
 
(3)  
Includes 437,345 shares underlying stock options
 
(4)  
Includes 41,668 shares owned by CJE Holdings, LLC (“CJE”) and 33,333 shares issuable upon conversion of Series A Preferred Stock.  Dr. Eagle exercises voting control and control over the disposition of all securities held CJE.
 
(5)  
Includes 100,000 shares owned by Concorde Investment Corporation, Mr. Sheth disclaims beneficial ownership of Concorde Investment Corporation.
 
(6)  
The address of Mosaic Capital Advisors, LLC is 400 Madison Avenue, Suite 6B, New York, New York 10017.
 
(7)  
Includes: (i) 1,083,334 common shares issuable under warrants; (ii) 1,567,895 shares issuable upon conversion of Series A Preferred Stock; (iii) 4,356,671 shares issuable upon conversion of Series B Preferred Stock; and (iv) 555,556 common shares issuable upon conversion of 500 shares of Series A Preferred Stock which are issuable upon conversion of unsecured convertible debentures held by Joseph McDevitt, an affiliated accredited investor.
 
 
 

 
 
 
- 52 -

 
 
 

(8)  
Includes 500 shares of Series A Preferred Stock issuable upon conversion of unsecured convertible debentures held by Joseph McDevitt, an affiliated accredited investor.
 
(9)  
The address of Haresh Sheth is Galaxy Towers II, #37C, 7002 Boulevard East, Guttenberg, New Jersey 07093.
 
(10)  
Includes: (i) 30,166 shares owned by Janus Finance Corporation (“Janus Finance”); (ii) 281,953 shares owned by Woodfield Capital Services, Inc. (“Woodfield”); and (iii) 250,000 shares underlying stock options.   Mr. Sheth exercises voting control and control over the disposition of all securities held by Janus Finance and Woodfield.
 
(11)  
The address of Pinewood Trading Company is 1029 East Drive, Beaumont, Texas 77706.
 
(12)  
Includes (i) 849,880 common shares issuable under warrants; (ii) 56,,000 common shares issuable upon conversion of unsecured convertible debentures; and (iii) 666,668 common shares issuable upon conversion of Series B Preferred Stock.
 
(13)  
The address of H.D. Smith Wholesale Drug Co. is 3063 Fiat Avenue, Springfield, IL 62703.
 
(14)  
  Includes 902,778 common shares issuable upon conversion of Series C Preferred Stock.
 
(15)  
 The address of Hillair Capital Investments, LP is 330 Primrose Road, Suite 660, Burlingame, CA 94010.
 
(16)  
 Includes: (i) 1,600,007 common shares issuable under warrants; and (ii) 1,111,114 common shares issuable upon conversion of unsecured convertible debentures.
 
(17)  
 The address of Baruch Halpern Revocable Trust is 9601 Collins Avenue PH 303, Bal Harbor, FL, 33154
 
(18)  
 Includes: (i) 400,000 common shares issuable under warrants; and (ii) 277,778 common shares issuable upon conversion of unsecured convertible debentures.
 
(19)  
 The address of Coventry Enterprises, LLC is 80 S.W. 8th Street, Suite 2000, Miami, FL 33130.
 
(20)  
Includes: (i) 320,000 common shares issuable under warrants; and (ii) 222,223 common shares issuable upon conversion of unsecured convertible debentures.
 
(21)  
The address of AQR Opportunistic Premium Offshore Fund, L.P. is Two Greenwich Plaza, 1st Floor, Two Greenwich, CT 06830
 
(22)  
Includes: (i) 320,002 common shares issuable under warrants; and (ii) 222,223 common shares issuable upon conversion of unsecured convertible debentures.
 
(23)  
The address of Jonathan Green is 7 Rumsen Trace, Carmel, CA 93923.